

09587116

Connecting via Winsock to STN

Trying 3106016892...Open

Welcome to STN International! Enter x:X

LOGINID:sssptal626amd

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Sep 17	IMSworld Pharmaceutical Company Directory name change to PHARMASEARCH
NEWS	3	Oct 09	Korean abstracts now included in Derwent World Patents Index
NEWS	4	Oct 09	Number of Derwent World Patents Index updates increased
NEWS	5	Oct 15	Calculated properties now in the REGISTRY/ZREGISTRY File
NEWS	6	Oct 22	Over 1 million reactions added to CASREACT
NEWS	7	Oct 22	DGENE GETSIM has been improved
NEWS	8	Oct 29	AAASD no longer available
NEWS	9	Nov 19	New Search Capabilities USPATFULL and USPAT2
NEWS	10	Nov 19	TOXCENTER(SM) - new toxicology file now available on STN
NEWS	11	Nov 29	COPPERLIT now available on STN
NEWS	12	Nov 29	DWPI revisions to NTIS and US Provisional Numbers
NEWS	13	Nov 30	Files VETU and VETB to have open access
NEWS	14	Dec 10	WPINDEX/WPIDS/WPIX New and Revised Manual Codes for 2002
NEWS	15	Dec 10	DGENE BLAST Homology Search
NEWS	16	Dec 17	WELDASEARCH now available on STN
NEWS	17	Dec 17	STANDARDS now available on STN
NEWS	18	Dec 17	New fields for DPCI
NEWS	19	Dec 19	CAS Roles modified
NEWS	20	Dec 19	1907-1946 data and page images added to CA and CPlus
NEWS EXPRESS			August 15 CURRENT WINDOWS VERSION IS V6.0c, CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP), AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

09587116

FILE 'HOME' ENTERED AT 16:21:30 ON 18 JAN 2002

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.15

0.15

FILE 'REGISTRY' ENTERED AT 16:21:41 ON 18 JAN 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 16 JAN 2002 HIGHEST RN 383858-27-3

DICTIONARY FILE UPDATES: 16 JAN 2002 HIGHEST RN 383858-27-3

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES  
for more information. See STNote 27, Searching Properties in the CAS  
Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>

Uploading 09587116.str

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful

FULL SEARCH INITIATED 16:22:10 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 9636 TO ITERATE

100.0% PROCESSED 9636 ITERATIONS

249 ANSWERS

SEARCH TIME: 00.00.06

L2 249 SEA SSS FUL L1

=> s l2 and caplus/lc

20179634 CAPLUS/LC

L3 240 L2 AND CAPLUS/LC

=> s l2 not l3

09587116

L4 9 L2 NOT L3

=>

Uploading 09587116.str

L5 STRUCTURE UPLOADED

=> d

L5 HAS NO ANSWERS

L5 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s 15 ful

FULL SEARCH INITIATED 16:23:17 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 9636 TO ITERATE

100.0% PROCESSED 9636 ITERATIONS

232 ANSWERS

SEARCH TIME: 00.00.03

L6 232 SEA SSS FUL L5

=> s 16 and caplus/lc

20179634 CAPLUS/LC

L7 223 L6 AND CAPLUS/LC

=> s 16 not 17

L8 9 L6 NOT L7

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

289.08

289.23

FILE 'CAPLUS' ENTERED AT 16:23:51 ON 18 JAN 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1907 - 18 Jan 2002 VOL 136 ISS 3

FILE LAST UPDATED: 16 Jan 2002 (20020116/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

09587116

CAplus now provides online access to patents and literature covered in CA from 1907 to the present. Bibliographic information and abstracts were added in 2001 for over 3.8 million records from 1907-1966.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

Attention, the CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

=> s 17


L9            58 L7

=> d 1-5 ibib abs hitstr







10. ANSWER: 2 OF 18 TAPUS: JULY 1987 2002 A13 (Continue)



Absolute stereochemistry.  
Double bond geometry unknown.




Absolute stereochemistry.  
Double bond geometry unknown.



RN 364750 04-9 CASUS  
 IN 19 Tetradepneumide, 4-hydroxy N [(3S)-tetrahydro-2H-pyran-3-yl]-  
 (9CI)  
 (CA INDEX NAME)

U. ANSWER : 2. In "AFTER THE BATTLE" THE AUTHOR (1) MENTIONED  
ALSO OTHER STATE MEMBERS.




REFERENCE COUNT: 1  
 REFERENCE(S):  
 "AIDS"  
 (1) *Cheney, S. J. ANCIENT 1989, Vol. 9, 1441*  
 (2) *Berhard, A. ANTHROPOLOGICAL 1989, Vol. 9, 1441*  
 (3) *Evans, M. W. GENEALOGY 1989, Vol. 9, 1441*  
 (4) *Evans, M. W. 1989-1992, 1993, 1994, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646,*

L2 ANSWER 3 OF 58 CALCULUS COPYRIGHT 2002 ADE

ACCESSION NUMBER:	20010606585 CAPUS
DOCUMENT NUMBER:	141209976
TITLE:	Oral solid dosage
N (1-hydroxyheptal-yl)-	am- $\gamma$ -gamma.
INVENTOR(S):	Eutry; late-time manufacture with Sphing miao
PATENT ASSIGNER(S):	Onkyo, Hiroshima; Kamai, Fui
SOURCE:	Onkyo, Hiroshima; Late-time with K. W., Japan
	Shio, Y. Kato, T. Kato, K. K. S. S. S.
	ORDEN: 0000AF
DOCUMENT TYPE:	
LAW FIRM:	Japanesse
FAMILY APP. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001247859	A2	2001.09.11	0 2000-57630	2000.09.26

LG ANSWER 3 OF 58 TAFLUS COPYRIGHT 2002 AOL (Continued)



AB The title compound (I), an inhibitor of amyloid precursor (alpha)-  
butyrolactase-binding protein of Gram-negative bacteria, is made, with  
Sphingomonas tyfermii. The I can be chem. synthesized by dehydration  
condensation of (R)-3-hydroxyheptan-1-ol and (S)-2-aminobutanoic  
butyrolactone. I is useful for inhibition of bacterial signal.

```

17      TRANSITION=
18      358259-35-00
19      KIL BEN (F) Synthesis: preparation of BEN Synthesis: preparation of BEN
20      (B) General studies: BEN (Preparation)
21      Optimal active N-1
22      -hydroxybenzyl-2-amino-1,3,4,5-tetrahydronaphthalene-1-carboxamide
23      -amide with spinel n.m.
24      358259-35-00
25      N-1,3,4,5-tetrahydronaphthalene-1-carboxamide
26      358259-35-00
27      (* INDEX NAME)

```

At a late stage, however,








09587116

=> d 6-58 ibib abs hitstr

[illegible][illegible]

AGE 105- 2500- 1401217Y.




```

REFERENCE COUNT: 58
REFERENCE(1):
(1) Armit, R. R. Natl Acad Sci 1985, V86, 14661
    CAPUS
(2) Kuchler, R. M. M. M. R. 1973, V89, P1287
    CAPUS
(3) Smith, R. K. R. Shoen 1992, V88, P897 CAPUS
(4) Smith, R. K. R. Shoen 1994, V87, 1434
    CAPUS
(5) Smith, R. K. M. M. R. 1994, V87, 1434
    CAPUS
ALL CITATIONS AVAILABLE IN THE EE VCAT

```

[illegible]

19. ANSWER: 7 OF 58 CARLOS COPYRIGHT 2002 ACS. [Continue!](#)  
Also like stereochemistry.



RN 330007-01-4 CAPLIN  
 IN 16-phenylamide,  
 2-phenyl-N-[4-(phenylamino)phenyl] N'-(1,3,5-trimethyl-  
 2-methyl-1H-1,2,4-triazol-4-yl) (501) (A INDEX NAME.

Also: life-size chemistry.



IN 00007 34 2 CAPLUS  
N 10 Propionamide,  
N-(2, 4-dihydro-1-propyl-4H and 1, 6-ylo-2-phenyl N' 1, 3, 5-  
tetrahydro-2, 4, 8, 4-tetraazolo-9, 7) 10A INDEX NAME

### Abstract



```

*****E *****
*****E *****
1) All-India Ind. B. 17-670 A 1977 TALMO
2) M. G. L. Ind. B. 17-670 A 1977 TALMO
3) M. G. L. Ind. B. 17-670 A 1977 TALMO
4) M. G. L. Ind. B. 17-670 A 1977 TALMO
5) M. G. L. Ind. B. 17-670 A 1977 TALMO

```

























09587116

16 ANSWER 21 OF 54 WEBCOR COPYRIGHT 2002 AND 2003









09587116

ANSWER: D. FIVE "AFTER" EIGHT MORE ARE "continued"



09587116

ANSWER: E. \* PALSING: MAY 1987, 1002, 472. \* 0106164

DATE : A




PN 204299-50-7 A1215

[illegible]

methionyl-L-leucyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-tyrosyl-N-(1,2,3,4-tetrahydro-2H-x<sup>3</sup>-6-oxo-1H-pyran-5-yl)-1,2,3,4-tetrahydro-2H-x<sup>3</sup>-6-oxo-1H-pyran-5-yl


Absolute stereochemistry.

TABLE 1-5




ANSWER 31 P. 54 TALLIS COPYRIGHT LTD. AND PUBLISHED BY

PAGE : 5



1000




BN 204260-92-1 CAMELUS

L-Serineamide,  
 L-leucyl-L-leucyl-L-tyrosyl-L-tyrosyl-L-tyrosyl-L-phenyl-L-phenyl-L-  
 tyrosyl-L-tyrosyl-L-tyrosyl-L-phenyl-L-tyrosyl-L-tyrosyl-L-tyrosyl-L-tyrosyl-L-  
 L-leucyl-L-methionyl-L-leucyl-L-leucyl-L-tyrosyl-L-tyrosyl-L-tyrosyl-L-tyrosyl-L-

L9 ANSWER 21 OF 44 CAPLUS COPYRIGHT 1992 AUS (Continued)  
N=[13S; tetrahydro-2H-x[3]furanyl]-[2-IL] (7A INDEX NAME


Absolute stereochemistry.

DATE: \_\_\_\_\_




04 ANSWER 21 OF 58 TALLIS COPYRIGHT 2002 ACS (Continued)

PAGE 17



PAGE 1-2

PAGE 1 F



FM 204260-64-6 TAF L'IS


\*crypt-phenyl-1-trypsin-phenyl-6-pyr-lyl-6-tryptophan-phenyl-6-or-lyl-8-6-tetrazinyl-  
2-x-3-foranyl) 97% KA INDEX NAME:

Are there stereo isomers?

09587116

ANSWER 21 OF 55: JULIUS VERNEHT 2:00 AM (7/24/2016)

1A22 : A



ANSWER: 11. F. CR. CALENDAR YEAR: 2002 AGE: 17 SEX: M

PAGE 1-4



CASE 2-A



PAGE 2-P



18 ANSWER 21 OF 58 CALPUS TWILIGHT 2002 AJS (Continued)

LN 204250 55 5 CAFLUS


CN L-Lysinamide,

[illegible]

tryptophyl-L-tryptophyl-L-tryptophyl-L-tryptophyl-N-(37)-tetrahyli-2- x -3-  
furanly] (901) (TA INDEX NAME)


Also late stereo-chemistry.

PAGE : 8




L9 ANSWER 21 OF 59 CAPLOS COPYRIGHT 2006 A33 57 (continued)

PAGE 1 B



SAEF : A



PAGE 2-5



29 1425-1430 Al<sup>3+</sup>

<sup>a</sup>  $\chi^2 = 79.01$ ,  $df = 10$ .

[illegible]

























09587116

19 ANSWER 2 OF 59 VALUE PRINTED 2.00 A.C. 11/11/2011

09587116

14 ANSWER 22 OF 54 CASINO COPYRIGHT 2002 ADO (continued)

FIGURE 1





FIGURE 2 A




FIGURE 2 B



17 201544-41-4P 201544-42-5P 201544-43-6P  
201544-44-7P 201544-45-8P 201544-46-9P  
201544-47-0P 201544-48-1P 201544-49-2P


14 ANSWER 22 OF 54 CASINO COPYRIGHT 2002 ADO (continued)

FIGURE 1-B



18 201544-42-5 CASINO  
19 201544-43-6 CASINO  
20 201544-44-7 CASINO  
21 201544-45-8 CASINO  
22 201544-46-9 CASINO  
23 201544-47-0 CASINO  
24 201544-48-1 CASINO  
25 201544-49-2 CASINO

FIGURE 1 A




14 ANSWER 22 OF 54 CASINO COPYRIGHT 2002 ADO (continued)

201544-50-3P 201544-51-4P 201544-52-5P 201544-53-6P  
201544-54-7P 201544-55-8P 201544-56-9P  
201544-57-0P 201544-58-1P 201544-59-2P  
201544-60-3P 201544-61-4P 201544-62-5P 201544-63-6P  
201544-64-7P 201544-65-8P 201544-66-9P  
201544-67-0P 201544-68-1P 201544-69-2P  
201544-70-3P 201544-71-4P 201544-72-5P  
201544-73-6P 201544-74-7P 201544-75-8P  
201544-76-9P

26 201544-77-0P 201544-78-1P 201544-79-2P 201544-80-3P  
201544-81-4P 201544-82-5P 201544-83-6P 201544-84-7P  
201544-85-8P 201544-86-9P 201544-87-0P 201544-88-1P  
201544-89-2P 201544-90-3P 201544-91-4P 201544-92-5P  
201544-93-6P 201544-94-7P 201544-95-8P 201544-96-9P  
201544-97-0P 201544-98-1P 201544-99-2P 201544-100-3P


See also other chemistry.

FIGURE 1 A



14 ANSWER 22 OF 54 CASINO COPYRIGHT 2002 ADO (continued)

FIGURE 2 A



26 201544-77-0P 201544-78-1P 201544-79-2P 201544-80-3P  
201544-81-4P 201544-82-5P 201544-83-6P 201544-84-7P  
201544-85-8P 201544-86-9P 201544-87-0P 201544-88-1P  
201544-89-2P 201544-90-3P 201544-91-4P 201544-92-5P  
201544-93-6P 201544-94-7P 201544-95-8P 201544-96-9P  
201544-97-0P 201544-98-1P 201544-99-2P 201544-100-3P

See also other chemistry.




















09587116

19 ANSWER 22 OF 58 CAPLUS COPYRIGHT 2002 ADS (continued)

IN 20144-74-1 CAPLUS  
TN L-tyrosinamide, L-alanyl-L-tyrosyl-L-alanyl-L-glutamyl-L-glutamyl-L-tyr-  
tetrathyl-L-x-3-furyl-L- (Sufedawill) lactam (90) (TA INDEX NAME)

Also like stereo chemistry.

PAGE 1-A



19 ANSWER 22 OF 58 CAPLUS COPYRIGHT 2002 ADS (continued)

PAGE 1-B



IN 20144-74-1 CAPLUS


TN L-tyrosinamide,

L-alanyl-L-tyrosyl-L-alanyl-L-glutamyl-L-glutamyl-L-tyr-  
tetrathyl-L-x-3-furyl-L- (Sufedawill) lactam (90) (TA INDEX NAME)

Also like stereo chemistry.

19 ANSWER 22 OF 58 CAPLUS COPYRIGHT 2002 ADS (continued)

PAGE 1-A



PAGE 1-B



19 ANSWER 22 OF 58 CAPLUS COPYRIGHT 2002 ADS (continued)

tetrathyl-L-x-3-furyl-L- (Sufedawill) lactam (90) (TA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*


IN 20144-74-1 CAPLUS

TN L-tyrosinamide,

L-alanyl-L-tyrosyl-L-alanyl-L-glutamyl-L-glutamyl-L-tyr-  
tetrathyl-L-x-3-furyl-L- (Sufedawill) lactam (90) (TA INDEX NAME)


Also like stereo chemistry.

PAGE 1-A





ANSWER 23 OF 44: ALUMINUM HYDROXIDE SOLID AKA: ALUMINA



ATTENTION NUMBER: 1497592222 APF00  
DOCUMENT NUMBER: 127225.40  
TITLE: A. H. MERRILL (ATTORNEY) (REDACTED)  
VOLUME: 2

UNIVERSITY, MICHIGAN, IQ, MICHIGAN, MI.  
 1. BARNETT, L. 1947, 178178, 5168-5181  
 GEN: 178178; 1947: 5168-5181  
 American Society for Microbiology  
 (1947)


by avirulent *X. nematophilus* and lowered the phenoloxidase activity in the

with HBHL. Culture on extra-f-medium conditioned with wild-type but a avirulent *X. nematophilus* led to the isolation of a  $\Delta$  copy with the same

compared to HENL and an almost identical manner and ;  
their effects on the luminousness of film are indistinguishable and

Re: BSH (Biological study, unclassified); RSC (Rational study,  
immunogenic lactose and induced regulated virulence of  
mouse pathogenic bacterium, Klebsiella pneumoniae)

Ann. l'été 1896 - 1897.



ACCESSION NUMBER: 1997:334416 CAPLIS  
DOCUMENT NUMBER: 127:119145  
TITLE: Detecting and characterizing N-acyl-L-methionine  
lactone

STEPHEN K. DEPARTMENT OF BIOCHEMISTRY, UNIVERSITY OF ILLINOIS, CHICAGO, ILL.

PUBLISHER: National Academy of Sciences  
DOCUMENT TYPE: Journal  
LANGUAGE: English

```

1405 5' size 1: a gene that is regulated by an internal 5' With the
1406 example: 1
1407 Nucleotide: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832
```


we showed that no more than one or two as many as five detectable signals in the structures could be assumed tentatively in the basis of stability and not state. The important problem is related to the problem of

three of which had novel structural properties. These were identified as the 3-oxo- $\gamma$ -lactams N-benzoyl-, N-phenyl-, and N-tetraphenyl-

17 192803-12-0 192803-14-0 192803-16-2  
 FBI: ANT Analytic : FBI: for parties : ANT Analytic: entity

19 ANSWER: 24. 10% CARBON DIOXIDE. COPYRIGHT 2012 APT. 7. Utilized  
 18 Determining and characterizing system behavior. List the signal in the  
 17 time delay in minutes.  
 16 10.0% 10.0% CARBON  
 15 10.0% 10.0% CARBON  
 14 10.0% 10.0% CARBON  
 13 10.0% 10.0% CARBON  
 12 10.0% 10.0% CARBON  
 11 10.0% 10.0% CARBON  
 10 10.0% 10.0% CARBON  
 9 10.0% 10.0% CARBON  
 8 10.0% 10.0% CARBON  
 7 10.0% 10.0% CARBON  
 6 10.0% 10.0% CARBON  
 5 10.0% 10.0% CARBON  
 4 10.0% 10.0% CARBON  
 3 10.0% 10.0% CARBON  
 2 10.0% 10.0% CARBON  
 1 10.0% 10.0% CARBON

Aug. 1970 Star-Chemistry.




```

NN      19248-14-0  CACITP
NN      = tautom. is. + hydroxy N-(tetrahydro-2H-pyran-3-yl)-2H-pyran-3-ol
NN      1A
NN      (INDEX NAME)


```

Abstract: The purpose of this study was to investigate the effects of a 12-week training program on the physical and psychological health of elderly people. The study was conducted in a community center in a city in China. The participants were 60 elderly people, aged 65 and above, who were randomly divided into two groups: a control group and an experimental group. The control group received no intervention, while the experimental group received a 12-week training program. The training program consisted of aerobic exercise, strength training, and flexibility exercises. The physical health of the participants was assessed using a series of tests, including a 6-minute walk test, a handgrip strength test, and a balance test. The psychological health of the participants was assessed using a series of questionnaires, including the Geriatric Depression Scale (GDS), the Geriatric Anxiety Inventory (GAI), and the Geriatric Life Satisfaction Scale (GLSS). The results of the study showed that the experimental group had significantly better physical and psychological health than the control group after 12 weeks of training. The experimental group had a significantly higher 6-minute walk distance, a significantly higher handgrip strength, and a significantly better balance than the control group. The experimental group also had a significantly lower GDS score, a significantly lower GAI score, and a significantly higher GLSS score than the control group. These findings suggest that a 12-week training program can improve the physical and psychological health of elderly people.



HN 152983-16-2 CALLUS  
CN Hexahydro-3,4,7,8-tetrahydro-2H-1,4-benzoxazine-3-carboxylic acid  
(INDEX NAME)

Also late stereo chemistry.




11	ANALYSIS 16 (P. 8)	CALCULUS	MEYERHOF 2070	ANALYSIS
12	EXERCISE NUMBER:		1947125-433	2070
13	EXERCISE NUMBER:		1261230-432	
14	EXERCISE TITLE:		Repetitive use of verbal expressions for use	
15			as	
16	INVENTOR(S):	MICHAEL STALLER		
17	INVENTOR:	MICHAEL, PAUL STALLER, RICHARD HENNING-KAUMANN,		
18		WOLFGANG, URS KUCHLER, HANS YANAKOS AND E. H. 126		
19	PATENT ASSIGNEE(S):	F. H. MULLER, ZURICH, SWITZERLAND		
20	EXERCISE TITLE:	F. H. MULLER, ZURICH, SWITZERLAND		
21		EXERCISE TITLE, 48 pp.		
22	EXERCISE TITLE:	EXERCISE TITLE		
23	EXERCISE TITLE:	EXERCISE TITLE		
24	EXERCISE TITLE:	EXERCISE TITLE		
25	EXERCISE TITLE:	EXERCISE TITLE		
26	EXERCISE TITLE:	EXERCISE TITLE		
27	EXERCISE TITLE:	EXERCISE TITLE		
28	EXERCISE TITLE:	EXERCISE TITLE		
29	EXERCISE TITLE:	EXERCISE TITLE		
30	EXERCISE TITLE:	EXERCISE TITLE		
31	EXERCISE TITLE:	EXERCISE TITLE		
32	EXERCISE TITLE:	EXERCISE TITLE		
33	EXERCISE TITLE:	EXERCISE TITLE		
34	EXERCISE TITLE:	EXERCISE TITLE		
35	EXERCISE TITLE:	EXERCISE TITLE		
36	EXERCISE TITLE:	EXERCISE TITLE		
37	EXERCISE TITLE:	EXERCISE TITLE		
38	EXERCISE TITLE:	EXERCISE TITLE		
39	EXERCISE TITLE:	EXERCISE TITLE		
40	EXERCISE TITLE:	EXERCISE TITLE		
41	EXERCISE TITLE:	EXERCISE TITLE		
42	EXERCISE TITLE:	EXERCISE TITLE		
43	EXERCISE TITLE:	EXERCISE TITLE		
44	EXERCISE TITLE:	EXERCISE TITLE		
45	EXERCISE TITLE:	EXERCISE TITLE		
46	EXERCISE TITLE:	EXERCISE TITLE		
47	EXERCISE TITLE:	EXERCISE TITLE		
48	EXERCISE TITLE:	EXERCISE TITLE		
49	EXERCISE TITLE:	EXERCISE TITLE		
50	EXERCISE TITLE:	EXERCISE TITLE		
51	EXERCISE TITLE:	EXERCISE TITLE		
52	EXERCISE TITLE:	EXERCISE TITLE		
53	EXERCISE TITLE:	EXERCISE TITLE		
54	EXERCISE TITLE:	EXERCISE TITLE		
55	EXERCISE TITLE:	EXERCISE TITLE		
56	EXERCISE TITLE:	EXERCISE TITLE		
57	EXERCISE TITLE:	EXERCISE TITLE		
58	EXERCISE TITLE:	EXERCISE TITLE		
59	EXERCISE TITLE:	EXERCISE TITLE		
60	EXERCISE TITLE:	EXERCISE TITLE		
61	EXERCISE TITLE:	EXERCISE TITLE		
62	EXERCISE TITLE:	EXERCISE TITLE		
63	EXERCISE TITLE:	EXERCISE TITLE		
64	EXERCISE TITLE:	EXERCISE TITLE		
65	EXERCISE TITLE:	EXERCISE TITLE		
66	EXERCISE TITLE:	EXERCISE TITLE		
67	EXERCISE TITLE:	EXERCISE TITLE		
68	EXERCISE TITLE:	EXERCISE TITLE		
69	EXERCISE TITLE:	EXERCISE TITLE		
70	EXERCISE TITLE:	EXERCISE TITLE		
71	EXERCISE TITLE:	EXERCISE TITLE		
72	EXERCISE TITLE:	EXERCISE TITLE		
73	EXERCISE TITLE:	EXERCISE TITLE		
74	EXERCISE TITLE:	EXERCISE TITLE		
75	EXERCISE TITLE:	EXERCISE TITLE		
76	EXERCISE TITLE:	EXERCISE TITLE		
77	EXERCISE TITLE:	EXERCISE TITLE		
78	EXERCISE TITLE:	EXERCISE TITLE		
79	EXERCISE TITLE:	EXERCISE TITLE		
80	EXERCISE TITLE:	EXERCISE TITLE		
81	EXERCISE TITLE:	EXERCISE TITLE		
82	EXERCISE TITLE:	EXERCISE TITLE		
83	EXERCISE TITLE:	EXERCISE TITLE		
84	EXERCISE TITLE:	EXERCISE TITLE		
85	EXERCISE TITLE:	EXERCISE TITLE		
86	EXERCISE TITLE:	EXERCISE TITLE		
87	EXERCISE TITLE:	EXERCISE TITLE		
88	EXERCISE TITLE:	EXERCISE TITLE		
89	EXERCISE TITLE:	EXERCISE TITLE		
90	EXERCISE TITLE:	EXERCISE TITLE		
91	EXERCISE TITLE:	EXERCISE TITLE		
92	EXERCISE TITLE:	EXERCISE TITLE		
93	EXERCISE TITLE:	EXERCISE TITLE		
94	EXERCISE TITLE:	EXERCISE TITLE		
95	EXERCISE TITLE:	EXERCISE TITLE		
96	EXERCISE TITLE:	EXERCISE TITLE		
97	EXERCISE TITLE:	EXERCISE TITLE		
98	EXERCISE TITLE:	EXERCISE TITLE		
99	EXERCISE TITLE:	EXERCISE TITLE		
100	EXERCISE TITLE:	EXERCISE TITLE		

PATENT NO.	FIND DATE	APPLICATION NO.	DATE
EP 761673	A1 19270312	EP 149A-113908	13080306
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MT,			


[illegible]

(THEY SPOKE): MARPAT 116139-140

ANSWER KEY FOR ALGEBRA COPYRIGHT © 2002 A T O S

[illegible]

19 ANSWER: 26 OF 58 (44.8%) CORRECT 2011-10-16 11:15:16



10 ANSWER 27: F 18: 18000 19: 18000 20: 18000

[illegible][illegible]

AP The present invention relates to compounds useful in the treatment of  
proliferative disorders, type I neurofibromatosis, comprising a  
farnesyl:protein transferase inhibitor. Cell proliferation is inhibited  
by factor stimulated  $\alpha$ 1-antitrypsin-deficient NF1 Schwann cells  
preincubated with various amounts of a farnesyl protein transferase

17 156876-44-7P 156876-45-8P 156876-46-9P  
156876-47-0P 156876-48-1P 156876-51-6P  
156876-52-7P 156876-53-8P 187267-74-9P  
187267-75-0P 187267-76-1P 187327-62-4P  
187729-65-3P



19 ANSWER 27 OF 58 CALLUS COPYRIGHT 2001 A/S (Continued)

Preparation(s): THU (Therapeutic uses); P/L (biological studies); PREP (Preparation); UDS (Uses).

5-[12-amin-3-mercapto-propyl]amin-1-6-methyl-2-pr-pyl-N-  
(tetrahyde-1- $\alpha$ -x-3-yl)aryl-, [9S-13R-12S-8,5R-6S,4R,3R]] (94)

(A INDEX NAME)

Absolute stereochemistry,  
 double bond geometry as ch. 10.



FN 156076-45-R "AF L'S

[illegible]

INDEX NAME
INDEX

Air like state chemistry,  
futile had as matrix as above




EN 14683-4:2005

A

10 ANSWER 27 OF 56 CAPLUS COPYRIGHT 2002 ACS (Continued)

INDEX NAME

Abs. late stereochemistry.  
Double bond geometry as of W.




DOI: 10.1002/for

methylethyl-N-tetradecyl-2-methyl-2-butyl-1,3-dithiolane-4-thione

*J. Chem. Soc., Perkin Trans. 2*, 1970, 1681-1685.

Are data stereo-chemistry.  
[ title & stereo as in vol.



PM 154836-4000 "AF 113


[illegible]

INDEX NAME

Ads info more than twice.  
 7. 10/11/20 10:20 PM, 10/21/20.


09587116

13 ANSWER 27 OF 58 CAPUS COPYRIGHT 2002 ADS (Continued)



PN 156676-51-6 CAPUS  
 IN 1-phenylbenzamide,  $\alpha$ -[3-(2-amin-3-methoxy-pyrimidin-4-methyl-1-hydroxy)-N-tetrahydro-2-methyl-furanyl]-[2-[3-(2- $\alpha$ -[3-(2,4,6-trimethyl-5-oxo-1,2,4-triazin-3-yl)-2-oxo-1-furanyl]-1-oxo-1,2,4-triazin-3-yl)-2-oxo-1-furanyl]]-1-oxo-1,2,4-triazin-3-yl] (5%) (CA INDEX NAME)


Also like stereo-chemistry.  
 Double bond geometry as shown.



PN 156676-52-7 CAPUS  
 IN 1-phenylbenzamide,  $\alpha$ -[3-(2-amin-3-methoxy-pyrimidin-4-methyl-1-hydroxy)-N-tetrahydro-2-methyl-furanyl]-[2-[3-(2- $\alpha$ -[3-(2,4,6-trimethyl-5-oxo-1,2,4-triazin-3-yl)-2-oxo-1-furanyl]-1-oxo-1,2,4-triazin-3-yl)-2-oxo-1-furanyl]]-1-oxo-1,2,4-triazin-3-yl] (5%) (CA INDEX NAME)


Also like stereo-chemistry.

13 ANSWER 27 OF 58 CAPUS COPYRIGHT 2002 ADS (Continued)



PN 167267-94-3 CAPUS  
 IN 1-phenylbenzamide, 5-[[2-amin-3-methoxy-pyrimidin-4-methyl-1-hydroxy)-N-tetrahydro-2-methyl-furanyl]-[2-[3-(2- $\alpha$ -[3-(2,4,6-trimethyl-5-oxo-1,2,4-triazin-3-yl)-2-oxo-1-furanyl]-1-oxo-1,2,4-triazin-3-yl)-2-oxo-1-furanyl]]-1-oxo-1,2,4-triazin-3-yl] (5%) (CA INDEX NAME)

Also like stereo-chemistry.



PN 167267-96-1 CAPUS  
 IN 1-phenylbenzamide,  $\alpha$ -[3-(2-amin-3-methoxy-pyrimidin-4-methyl-1-hydroxy)-N-tetrahydro-2-methyl-furanyl]-[2-[3-(2- $\alpha$ -[3-(2,4,6-trimethyl-5-oxo-1,2,4-triazin-3-yl)-2-oxo-1-furanyl]-1-oxo-1,2,4-triazin-3-yl)-2-oxo-1-furanyl]]-1-oxo-1,2,4-triazin-3-yl] (5%) (CA INDEX NAME)


Also like stereo-chemistry.



PN 167267-92-4 CAPUS  
 IN 1-phenylbenzamide,  $\alpha$ -[3-(2-amin-3-methoxy-pyrimidin-4-methyl-1-hydroxy)-N-tetrahydro-2-methyl-furanyl]-[2-[3-(2- $\alpha$ -[3-(2,4,6-trimethyl-5-oxo-1,2,4-triazin-3-yl)-2-oxo-1-furanyl]-1-oxo-1,2,4-triazin-3-yl)-2-oxo-1-furanyl]]-1-oxo-1,2,4-triazin-3-yl] (5%) (CA INDEX NAME)

Also like stereo-chemistry.  
 Double bond geometry as shown.

13 ANSWER 27 OF 58 CAPUS COPYRIGHT 2002 ADS (Continued)



PN 166676-53-8 CAPUS  
 IN 1-phenylbenzamide,  $\alpha$ -[3-(2-amin-3-methoxy-pyrimidin-4-methyl-1-hydroxy)-N-tetrahydro-2-methyl-furanyl]-[2-[3-(2- $\alpha$ -[3-(2,4,6-trimethyl-5-oxo-1,2,4-triazin-3-yl)-2-oxo-1-furanyl]-1-oxo-1,2,4-triazin-3-yl)-2-oxo-1-furanyl]]-1-oxo-1,2,4-triazin-3-yl] (5%) (CA INDEX NAME)


Also like stereo-chemistry.  
 Double bond geometry as shown.



PN 167267-74-1 CAPUS  
 IN 1-phenylbenzamide,  $\alpha$ -[3-(2-amin-3-methoxy-pyrimidin-4-methyl-1-hydroxy)-N-tetrahydro-2-methyl-furanyl]-[2-[3-(2- $\alpha$ -[3-(2,4,6-trimethyl-5-oxo-1,2,4-triazin-3-yl)-2-oxo-1-furanyl]-1-oxo-1,2,4-triazin-3-yl)-2-oxo-1-furanyl]]-1-oxo-1,2,4-triazin-3-yl] (5%) (CA INDEX NAME)

Also like stereo-chemistry.  
 Double bond geometry as shown.

13 ANSWER 27 OF 58 CAPUS COPYRIGHT 2002 ADS (Continued)



PN 167267-95-9 CAPUS  
 IN 1-phenylbenzamide, 5-[[2-amin-3-methoxy-pyrimidin-4-methyl-1-hydroxy)-N-tetrahydro-2-methyl-furanyl]-[2-[3-(2- $\alpha$ -[3-(2,4,6-trimethyl-5-oxo-1,2,4-triazin-3-yl)-2-oxo-1-furanyl]-1-oxo-1,2,4-triazin-3-yl)-2-oxo-1-furanyl]]-1-oxo-1,2,4-triazin-3-yl] (5%) (CA INDEX NAME)

Also like stereo-chemistry.  
 Double bond geometry as shown.



PN 167267-96-1 CAPUS  
 IN 1-phenylbenzamide,  $\alpha$ -[3-(2-amin-3-methoxy-pyrimidin-4-methyl-1-hydroxy)-N-tetrahydro-2-methyl-furanyl]-[2-[3-(2- $\alpha$ -[3-(2,4,6-trimethyl-5-oxo-1,2,4-triazin-3-yl)-2-oxo-1-furanyl]-1-oxo-1,2,4-triazin-3-yl)-2-oxo-1-furanyl]]-1-oxo-1,2,4-triazin-3-yl] (5%) (CA INDEX NAME)

Also like stereo-chemistry.



PN 167267-92-4 CAPUS  
 IN 1-phenylbenzamide,  $\alpha$ -[3-(2-amin-3-methoxy-pyrimidin-4-methyl-1-hydroxy)-N-tetrahydro-2-methyl-furanyl]-[2-[3-(2- $\alpha$ -[3-(2,4,6-trimethyl-5-oxo-1,2,4-triazin-3-yl)-2-oxo-1-furanyl]-1-oxo-1,2,4-triazin-3-yl)-2-oxo-1-furanyl]]-1-oxo-1,2,4-triazin-3-yl] (5%) (CA INDEX NAME)


Also like stereo-chemistry.  
 Double bond geometry as shown.






09587116

13 ANSWER 28 OF 58 CASUS COPYRIGHT 2002 ACS (continued)



IN 1567611-6 CASUS  
IN Cyclohexanecarboxamide,  $\alpha$ -(1-[(2-amin-3-mercaptoethyl)amino]-4-methyl-1-benzoyl-N-tetrahydropyridin-2(1H)-yl)furan-2(5H)-one (1:1)  
[1567611-6(1,2,3,4,5,6,7,8,9,10,11)] (1:1) (CA INDEX NAME)


Also late stereochemistry.  
Double bond is methyl as shown.



IN 1567612-7 CASUS  
IN Cyclohexanecarboxamide,  $\alpha$ -(1-[(2-amin-3-mercaptoethyl)amino]-4-methyl-1-benzoyl-N-tetrahydropyridin-2(1H)-yl)furan-2(5H)-one (1:1)  
[1567612-7(1,2,3,4,5,6,7,8,9,10,11)] (1:1) (CA INDEX NAME)


Also late stereochemistry.

13 ANSWER 29 OF 58 CASUS COPYRIGHT 2002 ACS (continued)



IN 15726775-0 CASUS  
IN Cyclohexanecarboxamide,  $\alpha$ -(1-[(2-amin-3-mercaptoethyl)amino]-4-methyl-1-benzoyl-N-tetrahydropyridin-2(1H)-yl)furan-2(5H)-one (1:1)  
[15726775-0(1,2,3,4,5,6,7,8,9,10,11)] (1:1) (CA INDEX NAME)

Also late stereochemistry.



IN 15726776-1 CASUS  
IN Cyclohexanecarboxamide,  $\alpha$ -(1-[(2-amin-3-mercaptoethyl)amino]-4-methyl-1-benzoyl-N-tetrahydropyridin-2(1H)-yl)furan-2(5H)-one (1:1)  
[15726776-1(1,2,3,4,5,6,7,8,9,10,11)] (1:1) (CA INDEX NAME)


Also late stereochemistry.



IN 15726777-4 CASUS  
IN Cyclohexanecarboxamide,  $\alpha$ -(1-[(2-amin-3-mercaptoethyl)amino]-4-methyl-1-benzoyl-N-tetrahydropyridin-2(1H)-yl)furan-2(5H)-one (1:1)  
[15726777-4(1,2,3,4,5,6,7,8,9,10,11)] (1:1) (CA INDEX NAME)


Also late stereochemistry.  
Double bond is methyl as shown.

13 ANSWER 30 OF 58 CASUS COPYRIGHT 2002 ACS (continued)




IN 15676113-8 CASUS  
IN Cyclohexanecarboxamide,  $\alpha$ -(1-[(2-amin-3-mercaptoethyl)amino]-4-methyl-1-benzoyl-N-tetrahydropyridin-2(1H)-yl)furan-2(5H)-one (1:1)  
[15676113-8(1,2,3,4,5,6,7,8,9,10,11)] (1:1) (CA INDEX NAME)

Also late stereochemistry.  
Double bond is methyl as shown.




IN 15726774-9 CASUS  
IN Cyclohexanecarboxamide,  $\alpha$ -(1-[(2-amin-3-mercaptoethyl)amino]-4-methyl-1-benzoyl-N-tetrahydropyridin-2(1H)-yl)furan-2(5H)-one (1:1)  
[15726774-9(1,2,3,4,5,6,7,8,9,10,11)] (1:1) (CA INDEX NAME)

Also late stereochemistry.  
Double bond is methyl as shown.




13 ANSWER 31 OF 58 CASUS COPYRIGHT 2002 ACS (continued)



IN 15726778-2 CASUS  
IN Cyclohexanecarboxamide,  $\alpha$ -(1-[(2-amin-3-mercaptoethyl)amino]-4-methyl-1-benzoyl-N-tetrahydropyridin-2(1H)-yl)furan-2(5H)-one (1:1)  
[15726778-2(1,2,3,4,5,6,7,8,9,10,11)] (1:1) (CA INDEX NAME)

Also late stereochemistry.



IN 15726779-3 CASUS  
IN Cyclohexanecarboxamide,  $\alpha$ -(1-[(2-amin-3-mercaptoethyl)amino]-4-methyl-1-benzoyl-N-tetrahydropyridin-2(1H)-yl)furan-2(5H)-one (1:1)  
[15726779-3(1,2,3,4,5,6,7,8,9,10,11)] (1:1) (CA INDEX NAME)

Also late stereochemistry.



IN 15726780-4 CASUS  
IN Cyclohexanecarboxamide,  $\alpha$ -(1-[(2-amin-3-mercaptoethyl)amino]-4-methyl-1-benzoyl-N-tetrahydropyridin-2(1H)-yl)furan-2(5H)-one (1:1)  
[15726780-4(1,2,3,4,5,6,7,8,9,10,11)] (1:1) (CA INDEX NAME)

Also late stereochemistry.  
Double bond is methyl as shown.


09587116

16 ANSWER 29 OF 58 CAPLUS (EVIDENT 2002 A)S  
 ACCESSION NUMBER: 10671190 CAPLUS  
 DOCUMENT NUMBER: 10671190  
 TITLE: Anticancer activity of a cyclic  
 last ferritin-derived  
 peptide  
 AUTHOR(S):  
 Hsu, Kaitien; Miller, James M.; Brown, David  
 A.;  
 DATE SUBMITTED: 14 April 2002  
 DATE RECEIVED: 14 April 2002  
 DATE INDEXED: 14 April 2002  
 DATE OF PUBLICATION: 14 April 2002

PUBLISHED: 14 April 2002  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB: Several peptides sharing high sequence homology with last ferritin B (LF-B) were generated from a cyclic last ferritin (LF) with two methionine  
 cysteine  
 peptides were purified, no identical LF, but with other  
 differing in half the length of a terminal alanine  
 chain (LF-B). The peptides were purified by a  
 column chromatography, no differing in half the length of  
 a terminal alanine-leucine and the other being a heterodimer linked  
 by a  
 disulfide bond. These peptides were isolated in a single step from  
 LF-B and analyzed by reverse phase high-pressure liquid chromatography (RP-HPLC).  
 They were  
 characterized by N-terminal Edman sequencing, mass spectrometry, and  
 antimicrobial activity tests. Pure last ferritin (LF-B) was  
 purified by reverse phase high-pressure liquid chromatography (RP-HPLC).  
 The  
 peptide was analyzed against a panel of gram-positive and gram-negative  
 bacteria.  
 Before and after reduction, the disulfide bond of the peptide after its  
 methionine residue was found to inhibit the growth of all the  
 bacteria at 100 µg/ml. If it required 100 µg/ml. Subfragment 1  
 last ferritin  
 were up to 100 µg/ml reduced and released peptide by reverse phase HPLC.  
 Subfragment 1 (residues 1-10) was active against most of the test  
 microorganisms at 100 µg/ml. Subfragment 2 (residues  
 11-25)  
 was active against only a few microorganisms at 100 µg/ml. If required  
 100 µg/ml.  
 These antimicrobial studies indicate that the activity of  
 last ferritin is  
 mainly, but not wholly, due to its N-terminal region.


17 ANSWER 29 OF 58 CAPLUS (EVIDENT 2002 A)S  
 ACCESSION NUMBER: 10671190 CAPLUS  
 DOCUMENT NUMBER: 10671190  
 TITLE: Anticancer activity of a cyclic  
 last ferritin-derived  
 peptide  
 AUTHOR(S):  
 Hsu, Kaitien; Miller, James M.; Brown, David  
 A.;  
 DATE SUBMITTED: 14 April 2002  
 DATE RECEIVED: 14 April 2002  
 DATE INDEXED: 14 April 2002  
 DATE OF PUBLICATION: 14 April 2002

AB: Several peptides sharing high sequence homology with last ferritin B (LF-B) were generated from a cyclic last ferritin (LF) with two methionine



16 ANSWER 29 OF 58 CAPLUS (EVIDENT 2002 A)S

PAGE 2-A



17 ANSWER 29 OF 58 CAPLUS (EVIDENT 2002 A)S  
 ACCESSION NUMBER: 10671190 CAPLUS  
 DOCUMENT NUMBER: 10671190  
 TITLE: Anticancer activity of a cyclic  
 last ferritin-derived  
 peptide  
 AUTHOR(S):  
 Hsu, Kaitien; Miller, James M.; Brown, David  
 A.;  
 DATE SUBMITTED: 14 April 2002  
 DATE RECEIVED: 14 April 2002  
 DATE INDEXED: 14 April 2002  
 DATE OF PUBLICATION: 14 April 2002

AB: Several peptides sharing high sequence homology with last ferritin B (LF-B) were generated from a cyclic last ferritin (LF) with two methionine








09587116

L5 ANSWER 34 OF 58 CALU/92 COPYRIGHT 2002 AND (C) BILLOWE


PAGE 1 OF 2

000000

PAGE 2 OF 2




PAGE 3 OF 2




L5 ANSWER 34 OF 58 CALU/92 COPYRIGHT 2002 AND (C) BILLOWE

L5 ANSWER 34 OF 58 CALU/92 COPYRIGHT 2002 AND (C) BILLOWE

PAGE 4 OF 2





PAGE 5 OF 2



L5 ANSWER 35 OF 58 CALU/92 COPYRIGHT 2002 AND (C) BILLOWE

ABSTRACT NUMBER: 1996146303  
 DOCUMENT NUMBER: 126106549  
 TITLE: The role of the lux auto-inducer in regulating luminescence in *Vibrio harveyi*: control of luxR expression.  
 AUTHOR(S): Miyamoto, Y; Mori, M.; Chatterjee, J; Ditty, B; Swartzman, E; Kato, S; Saito, K; Kato, H; Kato, A.  
 CORPORATE SOURCE: Leg. Biochem., McGill Univ., Montreal, PQ, H3A 2B4, CAN.  
 TYPE: Lab.  
 COUNTRY: MEXICO  
 DOCUMENT TYPE: JOURNAL  
 LANGUAGE: English  
 AB: Analysis of *Vibrio harveyi* dark auto-inducer mutants has demonstrated that the level of LuxR was much lower than that found in wild-type cells. Complementation with LuxR fully restored luminescence suggesting that the lux auto-inducer may control expression of the luxR regulatory gene. By primer extension, the transcriptional start site of luxR was located 75 bp upstream of the initiation +3 site. The level of the primer-extension product was enhanced 9-fold with the lux auto-inducer. The auto-inducer mutants, which were induced by hydrolysis of the auto-inducer, did not induce luxR. By using the luciferase-luxR gene fusion as a reporter gene, a transcriptional start site for luxR, the estimated size of the lux auto-inducer, and luxR expression was shown to be constant at the level of the luxR promoter. The results provide evidence that the auto-inducer signal in *V. harveyi* is transferred through luxR, resulting in stimulation of luxR expression.  
 ID: 126106549-72-7  
 E1: 126106549-72-7  
 E2: 126106549-72-7  
 E3: 126106549-72-7  
 E4: 126106549-72-7  
 E5: 126106549-72-7  
 E6: 126106549-72-7  
 E7: 126106549-72-7  
 E8: 126106549-72-7  
 E9: 126106549-72-7  
 E10: 126106549-72-7  
 E11: 126106549-72-7  
 E12: 126106549-72-7  
 E13: 126106549-72-7  
 E14: 126106549-72-7  
 E15: 126106549-72-7  
 E16: 126106549-72-7  
 E17: 126106549-72-7  
 E18: 126106549-72-7  
 E19: 126106549-72-7  
 E20: 126106549-72-7  
 E21: 126106549-72-7  
 E22: 126106549-72-7  
 E23: 126106549-72-7  
 E24: 126106549-72-7  
 E25: 126106549-72-7  
 E26: 126106549-72-7  
 E27: 126106549-72-7  
 E28: 126106549-72-7  
 E29: 126106549-72-7  
 E30: 126106549-72-7  
 E31: 126106549-72-7  
 E32: 126106549-72-7  
 E33: 126106549-72-7  
 E34: 126106549-72-7  
 E35: 126106549-72-7  
 E36: 126106549-72-7  
 E37: 126106549-72-7  
 E38: 126106549-72-7  
 E39: 126106549-72-7  
 E40: 126106549-72-7  
 E41: 126106549-72-7  
 E42: 126106549-72-7  
 E43: 126106549-72-7  
 E44: 126106549-72-7  
 E45: 126106549-72-7  
 E46: 126106549-72-7  
 E47: 126106549-72-7  
 E48: 126106549-72-7  
 E49: 126106549-72-7  
 E50: 126106549-72-7  
 E51: 126106549-72-7  
 E52: 126106549-72-7  
 E53: 126106549-72-7  
 E54: 126106549-72-7  
 E55: 126106549-72-7  
 E56: 126106549-72-7  
 E57: 126106549-72-7  
 E58: 126106549-72-7  
 E59: 126106549-72-7  
 E60: 126106549-72-7  
 E61: 126106549-72-7  
 E62: 126106549-72-7  
 E63: 126106549-72-7  
 E64: 126106549-72-7  
 E65: 126106549-72-7  
 E66: 126106549-72-7  
 E67: 126106549-72-7  
 E68: 126106549-72-7  
 E69: 126106549-72-7  
 E70: 126106549-72-7  
 E71: 126106549-72-7  
 E72: 126106549-72-7  
 E73: 126106549-72-7  
 E74: 126106549-72-7  
 E75: 126106549-72-7  
 E76: 126106549-72-7  
 E77: 126106549-72-7  
 E78: 126106549-72-7  
 E79: 126106549-72-7  
 E80: 126106549-72-7  
 E81: 126106549-72-7  
 E82: 126106549-72-7  
 E83: 126106549-72-7  
 E84: 126106549-72-7  
 E85: 126106549-72-7  
 E86: 126106549-72-7  
 E87: 126106549-72-7  
 E88: 126106549-72-7  
 E89: 126106549-72-7  
 E90: 126106549-72-7  
 E91: 126106549-72-7  
 E92: 126106549-72-7  
 E93: 126106549-72-7  
 E94: 126106549-72-7  
 E95: 126106549-72-7  
 E96: 126106549-72-7  
 E97: 126106549-72-7  
 E98: 126106549-72-7  
 E99: 126106549-72-7  
 E100: 126106549-72-7  
 E101: 126106549-72-7  
 E102: 126106549-72-7  
 E103: 126106549-72-7  
 E104: 126106549-72-7  
 E105: 126106549-72-7  
 E106: 126106549-72-7  
 E107: 126106549-72-7  
 E108: 126106549-72-7  
 E109: 126106549-72-7  
 E110: 126106549-72-7  
 E111: 126106549-72-7  
 E112: 126106549-72-7  
 E113: 126106549-72-7  
 E114: 126106549-72-7  
 E115: 126106549-72-7  
 E116: 126106549-72-7  
 E117: 126106549-72-7  
 E118: 126106549-72-7  
 E119: 126106549-72-7  
 E120: 126106549-72-7  
 E121: 126106549-72-7  
 E122: 126106549-72-7  
 E123: 126106549-72-7  
 E124: 126106549-72-7  
 E125: 126106549-72-7  
 E126: 126106549-72-7  
 E127: 126106549-72-7  
 E128: 126106549-72-7  
 E129: 126106549-72-7  
 E130: 126106549-72-7  
 E131: 126106549-72-7  
 E132: 126106549-72-7  
 E133: 126106549-72-7  
 E134: 126106549-72-7  
 E135: 126106549-72-7  
 E136: 126106549-72-7  
 E137: 126106549-72-7  
 E138: 126106549-72-7  
 E139: 126106549-72-7  
 E140: 126106549-72-7  
 E141: 126106549-72-7  
 E142: 126106549-72-7  
 E143: 126106549-72-7  
 E144: 126106549-72-7  
 E145: 126106549-72-7  
 E146: 126106549-72-7  
 E147: 126106549-72-7  
 E148: 126106549-72-7  
 E149: 126106549-72-7  
 E150: 126106549-72-7  
 E151: 126106549-72-7  
 E152: 126106549-72-7  
 E153: 126106549-72-7  
 E154: 126106549-72-7  
 E155: 126106549-72-7  
 E156: 126106549-72-7  
 E157: 126106549-72-7  
 E158: 126106549-72-7  
 E159: 126106549-72-7  
 E160: 126106549-72-7  
 E161: 126106549-72-7  
 E162: 126106549-72-7  
 E163: 126106549-72-7  
 E164: 126106549-72-7  
 E165: 126106549-72-7  
 E166: 126106549-72-7  
 E167: 126106549-72-7  
 E168: 126106549-72-7  
 E169: 126106549-72-7  
 E170: 126106549-72-7  
 E171: 126106549-72-7  
 E172: 126106549-72-7  
 E173: 126106549-72-7  
 E174: 126106549-72-7  
 E175: 126106549-72-7  
 E176: 126106549-72-7  
 E177: 126106549-72-7  
 E178: 126106549-72-7  
 E179: 126106549-72-7  
 E180: 126106549-72-7  
 E181: 126106549-72-7  
 E182: 126106549-72-7  
 E183: 126106549-72-7  
 E184: 126106549-72-7  
 E185: 126106549-72-7  
 E186: 126106549-72-7  
 E187: 126106549-72-7  
 E188: 126106549-72-7  
 E189: 126106549-72-7  
 E190: 126106549-72-7  
 E191: 126106549-72-7  
 E192: 126106549-72-7  
 E193: 126106549-72-7  
 E194: 126106549-72-7  
 E195: 126106549-72-7  
 E196: 126106549-72-7  
 E197: 126106549-72-7  
 E198: 126106549-72-7  
 E199: 126106549-72-7  
 E200: 126106549-72-7  
 E201: 126106549-72-7  
 E202: 126106549-72-7  
 E203: 126106549-72-7  
 E204: 126106549-72-7  
 E205: 126106549-72-7  
 E206: 126106549-72-7  
 E207: 126106549-72-7  
 E208: 126106549-72-7  
 E209: 126106549-72-7  
 E210: 126106549-72-7  
 E211: 126106549-72-7  
 E212: 126106549-72-7  
 E213: 126106549-72-7  
 E214: 126106549-72-7  
 E215: 126106549-72-7  
 E216: 126106549-72-7  
 E217: 126106549-72-7  
 E218: 126106549-72-7  
 E219: 126106549-72-7  
 E220: 126106549-72-7  
 E221: 126106549-72-7  
 E222: 126106549-72-7  
 E223: 126106549-72-7  
 E224: 126106549-72-7  
 E225: 126106549-72-7  
 E226: 126106549-72-7  
 E227: 126106549-72-7  
 E228: 126106549-72-7  
 E229: 126106549-72-7  
 E230: 126106549-72-7  
 E231: 126106549-72-7  
 E232: 126106549-72-7  
 E233: 126106549-72-7  
 E234: 126106549-72-7  
 E235: 126106549-72-7  
 E236: 126106549-72-7  
 E237: 126106549-72-7  
 E238: 126106549-72-7  
 E239: 126106549-72-7  
 E240: 126106549-72-7  
 E241: 126106549-72-7  
 E242: 126106549-72-7  
 E243: 126106549-72-7  
 E244: 126106549-72-7  
 E245: 126106549-72-7  
 E246: 126106549-72-7  
 E247: 126106549-72-7  
 E248: 126106549-72-7  
 E249: 126106549-72-7  
 E250: 126106549-72-7  
 E251: 126106549-72-7  
 E252: 126106549-72-7  
 E253: 126106549-72-7  
 E254: 126106549-72-7  
 E255: 126106549-72-7  
 E256: 126106549-72-7  
 E257: 126106549-72-7  
 E258: 126106549-72-7  
 E259: 126106549-72-7  
 E260: 126106549-72-7  
 E261: 126106549-72-7  
 E262: 126106549-72-7  
 E263: 126106549-72-7  
 E264: 126106549-72-7  
 E265: 126106549-72-7  
 E266: 126106549-72-7  
 E267: 126106549-72-7  
 E268: 126106549-72-7  
 E269: 126106549-72-7  
 E270: 126106549-72-7  
 E271: 126106549-72-7  
 E272: 126106549-72-7  
 E273: 126106549-72-7  
 E274: 126106549-72-7  
 E275: 126106549-72-7  
 E276: 126106549-72-7  
 E277: 126106549-72-7  
 E278: 126106549-72-7  
 E279: 126106549-72-7  
 E280: 126106549-72-7  
 E281: 126106549-72-7  
 E282: 126106549-72-7  
 E283: 126106549-72-7  
 E284: 126106549-72-7  
 E285: 126106549-72-7  
 E286: 126106549-72-7  
 E287: 126106549-72-7  
 E288: 126106549-72-7  
 E289: 126106549-72-7  
 E290: 126106549-72-7  
 E291: 126106549-72-7  
 E292: 126106549-72-7  
 E293: 126106549-72-7  
 E294: 126106549-72-7  
 E295: 126106549-72-7  
 E296: 126106549-72-7  
 E297: 126106549-72-7  
 E298: 126106549-72-7  
 E299: 126106549-72-7  
 E300: 126106549-72-7  
 E301: 126106549-72-7  
 E302: 126106549-72-7  
 E303: 126106549-72-7  
 E304: 126106549-72-7  
 E305: 126106549-72-7  
 E306: 126106549-72-7  
 E307: 126106549-72-7  
 E308: 126106549-72-7  
 E309: 126106549-72-7  
 E310: 126106549-72-7  
 E311: 126106549-72-7  
 E312: 126106549-72-7  
 E313: 126106549-72-7  
 E314: 126106549-72-7  
 E315: 126106549-72-7  
 E316: 126106549-72-7  
 E317: 126106549-72-7  
 E318: 126106549-72-7  
 E319: 126106549-72-7  
 E320: 126106549-72-7  
 E321: 126106549-72-7  
 E322: 126106549-72-7  
 E323: 126106549-72-7  
 E324: 126106549-72-7  
 E325: 126106549-72-7  
 E326: 126106549-72-7  
 E327: 126106549-72-7  
 E328: 126106549-72-7  
 E329: 126106549-72-7  
 E330: 126106549-72-7  
 E331: 126106549-72-7  
 E332: 126106549-72-7  
 E333: 126106549-72-7  
 E334: 126106549-72-7  
 E335: 126106549-72-7  
 E336: 126106549-72-7  
 E337: 126106549-72-7  
 E338: 126106549-72-7  
 E339: 126106549-72-7  
 E340: 126106549-72-7  
 E341: 126106549-72-7  
 E342: 126106549-72-7  
 E343: 126106549-72-7  
 E344: 126106549-72-7  
 E345: 126106549-72-7  
 E346: 126106549-72-7  
 E347: 126106549-72-7  
 E348: 126106549-72-7  
 E349: 126106549-72-7  
 E350: 126106549-72-7  
 E351: 126106549-72-7  
 E352: 126106549-72-7  
 E353: 126106549-72-7  
 E354: 126106549-72-7  
 E355: 126106549-72-7  
 E356: 126106549-72-7  
 E357: 126106549-72-7  
 E358: 126106549-72-7  
 E359: 126106549-72-7  
 E360: 126106549-72-7  
 E361: 126106549-72-7  
 E362: 126106549-72-7  
 E363: 126106549-72-7  
 E364: 126106549-72-7  
 E365: 126106549-72-7  
 E366: 126106549-72-7  
 E367: 126106549-72-7  
 E368: 126106549-72-7  
 E369: 126106549-72-7  
 E370: 126106549-72-7  
 E371: 126106549-72-7  
 E372: 126106549-72-7  
 E373: 126106549-72-7  
 E374: 126106549-72-7  
 E375: 126106549-72-7  
 E376: 126106549-72-7  
 E377: 126106549-72-7  
 E378: 126106549-72-7  
 E379: 126106549-72-7  
 E380: 126106549-72-7  
 E381: 126106549-72-7  
 E382: 126106549-72-7  
 E383: 126106549-72-7  
 E384: 126106549-72-7  
 E385: 126106549-72-7  
 E386: 126106549-72-7  
 E387: 126106549-72-7  
 E388: 126106549-72-7  
 E389: 126106549-72-7  
 E390: 126106549-72-7  
 E391: 126106549-72-7  
 E392: 126106549-72-7  
 E393: 126106549-72-7  
 E394: 126106549-72-7  
 E395: 126106549-72-7  
 E396: 126106549-72-7  
 E397: 126106549-72-7  
 E398: 126106549-72-7  
 E399: 126106549-72-7  
 E400: 126106549-72-7  
 E401: 126106549-72-7  
 E402: 126106549-72-7  
 E403: 126106549-72-7  
 E404: 126106549-72-7  
 E405: 126106549-72-7  
 E406: 126106549-72-7  
 E407: 126106549-72-7  
 E408: 126106549-72-7  
 E409: 126106549-72-7  
 E410: 126106549-72-7  
 E411: 126106549-72-7  
 E412: 126106549-72-7  
 E413: 126106549-72-7  
 E414: 126106549-72-7  
 E415: 126106549-72-7  
 E416: 126106549-72-7  
 E417: 126106549-72-7  
 E418: 126106549-72-7  
 E419: 126106549-72-7  
 E420: 126106549-72-7  
 E421: 126106549-72-7  
 E422: 126106549-72-7  
 E423: 126106549-72-7  
 E424: 126106549-72-7  
 E425: 126106549-72-7  
 E426: 126106549-72-7  
 E427: 126106549-72-7  
 E428: 126106549-72-7  
 E429: 126106549-72-7  
 E430: 126106549-72-7  
 E431: 126106549-72-7  
 E432: 126106549-72-7  
 E433: 126106549-72-7  
 E434: 126106549-72-7  
 E435: 126106549-72-7  
 E436: 126106549-72-7  
 E437: 126106549-72-7  
 E438: 126106549-72-7  
 E439: 126106549-72-7  
 E440: 126106549-72-7  
 E441: 126106549-72-7  
 E442: 126106549-72-7  
 E443: 126106549-72-7  
 E444: 126106549-72-7  
 E445: 126106549-72-7  
 E446: 126106549-72-7  
 E447: 126106549-72-7  
 E448: 126106549-72-7  
 E449: 126106549-72-7  
 E450: 126106549-72-7  
 E451: 126106549-72-7  
 E452: 126106549-72-7  
 E453: 126106549-72-7  
 E454: 126106549-72-7  
 E455: 126106549-72-7  
 E456: 126106549-72-7  
 E457: 126106549-72-7  
 E458: 126106549-72-7  
 E459: 126106549-72-7  
 E460: 126106549-72-7  
 E461: 126106549-72-7  
 E462: 126106549-72-7  
 E463: 126106549-72-7  
 E464: 126106549-72-7  
 E465: 126106549-72-7  
 E466: 126106549-72-7  
 E467: 126106549-72-7  
 E468: 126106549-72-7  
 E469: 12


1. ANSWER: "F" IS "APPLY" (LYE) BUT NOT "ADD" (ADD) "GIVEN"

[illegible][illegible]

```

09 ANSWER 36 OF 54 CAPLUS COPYRIGHT 2002 ATC (continued)
      (as anti-inhibitor if stat; vary phase and this where-expressed)
      (phase 1)
0N 172671-00-0 CAPLUS
0N Tetradecanamide, 2-hydroxy-N-(tetrahydro-2H-pyran-3-yl)-1,3-bis(1-phenyl-1H-tetrazol-5-yl)-
      (IUPAC NAME)
      1
0N 172671-00-4
      1,3-bis(1-phenyl-1H-tetrazol-5-yl)-2-hydroxy-N-(tetrahydro-2H-pyran-3-yl)tetradecanamide

```

[illegible]






48 Title: mp1 (K) = H<sub>2</sub>O, 4-alkyl, aralkyl, R<sup>1</sup> = aryl.  
 49 alkyl/arylmethyl.  
 50 aralkyl = aryl, alkyl/arylmethyl, n = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 82

*Agrostis stolonata* L.



09587116

19 ANSWER 40 OF 58 CAPLUS COPYRIGHT 2000 APO (2) (b)(6)



M 2  
 CEN 76 05 1  
 CME 02 H F 02



RN 156528-02-8 CAPLUS  
 TN 3 Heptetamide, 5-[(2-amin-2-methylpropyl)amino]-6-methyl-2-[(1-methyl-2-oxo-1,3-tetrahydropyridin-2-yl)-4-furanyl]-, [1S-[(1S\*,2S\*,3S\*,4S\*)]]], trifluoracetate (salt) (3:1) (A INDEX NAME)

M 1  
 CEN 15676-05 4  
 CME 018 H33 N3 O3 3  
 CDES \*

Atm lute stereo chemistry.  
 Double bond is methyl as shown.

19 ANSWER 40 OF 58 CAPLUS COPYRIGHT 2000 APO (2) (b)(6)



M 2  
 CEN 76 05 1  
 CME 02 H F 02




RN 156528-02-8 CAPLUS  
 TN 3 Heptetamide, 5-[(2-amin-2-methylpropyl)amino]-6-methyl-2-[(1-methyl-2-oxo-1,3-tetrahydropyridin-2-yl)-4-furanyl]-, [1S-[(1S\*,2S\*,3S\*,4S\*)]]], trifluoracetate (salt) (3:1) (A INDEX NAME)

M 1  
 CEN 15676-05 4  
 CME 018 H33 N3 O3 3  
 CDES \*

Atm lute stereo chemistry.

19 ANSWER 40 OF 58 CAPLUS COPYRIGHT 2000 APO (2) (b)(6)




M 2  
 CEN 76 05 1  
 CME 02 H F 02



RN 157026-02 7 CAPLUS  
 TN 3 5-oxo-2,6-bis(2-amin-2-methylpropyl)-2,6-dimethyl-2-oxo-1,3-tetrahydropyridin-4-yl-4-furanyl-, [1S-[(1S\*,2S\*,3S\*,4S\*)]]], trifluoracetate (salt) (A INDEX NAME)


M 1  
 CEN 157026-02 4  
 CME 020 H37 N3 O3 3

Atm lute stereo chemistry.  
 Double bond is methyl as shown.



M 2  
 CEN 76 05 1  
 CME 02 H F 02

19 ANSWER 40 OF 58 CAPLUS COPYRIGHT 2000 APO (2) (b)(6)




M 2  
 CEN 76 05 1  
 CME 02 H F 02



RN 167036-00 5 CAPLUS  
 TN 3 5-oxo-2,6-bis(2-amin-2-methylpropyl)-2,6-dimethyl-2-oxo-1,3-tetrahydropyridin-4-yl-4-furanyl-, [1S-[(1S\*,2S\*,3S\*,4S\*)]]], trifluoracetate (salt) (A INDEX NAME)

M 1  
 CEN 167036-00 4  
 CME 020 H37 N3 O3 3

Atm lute stereo chemistry.  
 Double bond is methyl as shown.



M 2  
 CEN 76 05 1  
 CME 02 H F 02

\_\_\_\_\_

[illegible][illegible]
$$\text{NH}-\text{C}(=\text{O})-\text{CH}_2-\text{CH}(\text{OH})-\text{Fuc}$$

### Allyl cation stereochemistry

Absolute stereochemistry:  
Double bond geometry as shown.

At the store chemistry,  
 I like it just as much as the wine.

Ann. N.Y. Acad. Sci. 1967, 197: 1-10.









1.  $\Delta \text{H}^\circ_{\text{f}}(\text{H}_2\text{O}(l)) = -285.8 \text{ kJ mol}^{-1}$   
 2.  $\Delta \text{H}^\circ_{\text{f}}(\text{H}_2\text{O}(g)) = -241.8 \text{ kJ mol}^{-1}$

09587116

L2 ANSWER 44 OF 58 CASUS COPYRIGHT 2002 ACS (continued)



RN 156476-51-6 CASUS

TN Cyl heptanamide, 4-[(2-amino-3-mercapto-propylamino)-4-methyl-1-hexenyl]-N-tetrayl-2,2,6,6-tetraol, (S)- [10\*([alpha]<sub>D</sub><sup>20</sup>[(18,18)(S),4R)])] (S)-1) (A INDEX NAME)Abn late stereochemistry.  
Double bond geometry as shown.

RN 156476-52-7 CASUS


TN Cyl heptanamide, 4-[(2-amino-3-mercapto-propylamino)-4-[(1,2-dimethyl-1-mercapto-propylamino)-4-methyl-1-hexenyl]-N-tetrayl-2,2,6,6-tetraol, (S)- [10\*([alpha]<sub>D</sub><sup>20</sup>[(18,18)(S),4R)])] (S)-1) (A INDEX NAME)Abn late stereochemistry.  
Double bond geometry as shown.

L2 ANSWER 44 OF 58 CASUS COPYRIGHT 2002 ACS (continued)


RN 156476-58-9 CASUS

TN heptanamide, 4-[(2-amino-3-mercapto-propylamino)-4-methyl-1-hexenyl]-N-tetrayl-2,2,6,6-tetraol, (S)- [10\*([alpha]<sub>D</sub><sup>20</sup>[(18,18)(S),4R)])] (S)-1) (A INDEX NAME)

Abn late stereochemistry.



RN 156476-55-4 CASUS

TN heptanamide, 4-[(2-amino-3-mercapto-propylamino)-4-methyl-1-hexenyl]-N-tetrayl-2,2,6,6-tetraol, (S)- [10\*([alpha]<sub>D</sub><sup>20</sup>[(18,18)(S),4R)])] (S)-1) (A INDEX NAME)Abn late stereochemistry.  
Double bond geometry as shown.


RN 156476-51-6 CASUS

TN heptanamide, 4-[(2-amino-3-mercapto-propylamino)-4-methyl-1-hexenyl]-N-tetrayl-2,2,6,6-tetraol, (S)- [10\*([alpha]<sub>D</sub><sup>20</sup>[(18,18)(S),4R)])] (S)-1) (A INDEX NAME)


M 1

RN 156476-51-6 CASUS  
MF 11 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

L2 ANSWER 44 OF 58 CASUS COPYRIGHT 2002 ACS (continued)




RN 156476-51-6 CASUS

TN heptanamide, 4-[(2-amino-3-mercapto-propylamino)-4-methyl-1-hexenyl]-N-tetrayl-2,2,6,6-tetraol, (S)- [10\*([alpha]<sub>D</sub><sup>20</sup>[(18,18)(S),4R)])] (S)-1) (A INDEX NAME)Abn late stereochemistry.  
Double bond geometry as shown.

RN 156476-57-2 CASUS


TN heptanamide, 4-[(2-amino-3-mercapto-propylamino)-4-methyl-2-propyl-N-tetrayl-2,2,6,6-tetraol, (S)- [10\*([alpha]<sub>D</sub><sup>20</sup>[(18,18)(S),4R)])] (S)-1) (A INDEX NAME)

Abn late stereochemistry.



L2 ANSWER 44 OF 58 CASUS COPYRIGHT 2002 ACS (continued)

Abn late stereochemistry.



M 2

TN 74 75 76  
MF 11 18 19 20

F

F=CH<sub>2</sub>,H

F

RN 156476-52-7 CASUS

TN heptanamide, 4-[(2-amino-3-mercapto-propylamino)-4-methyl-2-(1-methyl-2-propyl-N-tetrayl-2,2,6,6-tetraol, (S)- [10\*([alpha]<sub>D</sub><sup>20</sup>[(18,18)(S),4R)])] (S)-1) (A INDEX NAME)

M 1

TN 156476-51-6  
MF 11 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100Abn late stereochemistry.  
Double bond geometry as shown.

M 2

09587116

13 ANSWER 44 OF 58 TALLIS COPYRIGHT 2002 ADS (continued)

HN 76455.1  
MF C2 H F3 O2

F

F=O=O2H

F

RN 156874.44 TALLIS


N 1-phenylamino

[12] amino-1-mercaptopyrrolidine-1-bis(methyl-2-ethyl-N-methyl-2-oxo-4-tetrahydropyridin-3-yl)-1,3,5-triazole-2,4,6-trisulfonate (salt) (971) (TA INDEX NAME)

CH 1

HN 156874.44 T  
MF C13 H15 N3 O2 S  
TDES \*

Absolute stereochemistry.  
Double bond is messy as shown.




CH 2

HN 76455.1  
MF C2 H F3 O2

13 ANSWER 44 OF 58 TALLIS COPYRIGHT 2002 ADS (continued)

HN 156875.46 T  
MF C14 H15 N3 O2 S  
TDES \*

Absolute stereochemistry.  
Double bond is messy as shown.



CH 2

HN 76455.1  
MF C2 H F3 O2



RN 156875.46 TALLIS

N 1-phenylamino

[12] amino-1-mercaptopyrrolidine-1-bis(methyl-2-ethyl-N-methyl-2-oxo-4-tetrahydropyridin-3-yl)-1,3,5-triazole-2,4,6-trisulfonate (salt) (971) (TA INDEX NAME)

CH 1

HN 156875.46 T  
MF C13 H15 N3 O2 S  
TDES \*

Absolute stereochemistry.  
Double bond is messy as shown.

13 ANSWER 44 OF 58 TALLIS COPYRIGHT 2002 ADS (continued)



RN 156875.46 TALLIS

N 1-phenylamino-1-mercaptopyrrolidine-1-bis(methyl-2-ethyl-N-methyl-2-oxo-4-tetrahydropyridin-3-yl)-1,3,5-triazole-2,4,6-trisulfonate (salt) (971) (TA INDEX NAME)

CH 1

HN 156875.46 T  
MF C13 H15 N3 O2 S  
TDES \*

Absolute stereochemistry.  
Double bond is messy as shown.



CH 2

HN 76455.1  
MF C2 H F3 O2




RN 156875.46 TALLIS

N 1-phenylamino-1-mercaptopyrrolidine-1-bis(methyl-2-ethyl-N-methyl-2-oxo-4-tetrahydropyridin-3-yl)-1,3,5-triazole-2,4,6-trisulfonate (salt) (971) (TA INDEX NAME)

CH 1

13 ANSWER 44 OF 58 TALLIS COPYRIGHT 2002 ADS (continued)



CH 2

HN 76455.1  
MF C2 H F3 O2



RN 156875.46 TALLIS

N 1-phenylamino-1-mercaptopyrrolidine-1-bis(methyl-2-ethyl-N-methyl-2-oxo-4-tetrahydropyridin-3-yl)-1,3,5-triazole-2,4,6-trisulfonate (salt) (971) (TA INDEX NAME)

CH 1

HN 156875.46 T  
MF C13 H15 N3 O2 S  
TDES \*

Absolute stereochemistry.  
Double bond is messy as shown.



09587116

12 ANSWER 44 OF 54 CAPLUS COPYRIGHT 2002 APO (continued)


M 2  
CRN 76-04-1  
MF 02 H F3 12

F  
F = 0.02H  
F

PN 156927-00-0 CAPLUS  
CN 3,4-Dihexamide,  
N-[[[2-amino-3-methylpentan-3-yl]amino]-2-(1,1,1-trimethyl-ethyl)-5-methyl-1H-tetrazol-5-yl]-N-tetrazolyl-2,3,4-triazolyl-1,2,3-trifluoroacetate (salt) (901) (CA INDEX NAME)

CM 1  
CRN 156926-00-5  
MF 022 H19 N4 O4 2  
CLES \*

Also note stereochemistry.  
Double bond geometry as shown.



CM 2  
CRN 76-04-1  
MF 02 H F3 12


13 ANSWER 44 OF 54 CAPLUS COPYRIGHT 2002 APO (continued)

F  
F = 0.02H  
F

PN 156928-00-0 CAPLUS  
CN 3-[[[2-amino-3-methylpentan-3-yl]amino]-4-methyl-1,1,1-trimethyl-5-methyl-1H-tetrazol-5-yl]-N-tetrazolyl-2,3,4-triazolyl-1,2,3-trifluoroacetate (salt) (901) (CA INDEX NAME)

CM 1  
CRN 156926-02-7  
MF 021 H17 N4 O3 3  
CLES \*

Also note stereochemistry.  
Double bond geometry as shown.



CM 2  
CRN 76-04-1  
MF 02 H F3 12

F  
F = 0.02H  
F

PN 156928-01-0 CAPLUS  
CN Benzamide,  
N-[[[2-amino-3-methylpentan-3-yl]amino]-4-methyl-1,1,1-trimethyl-5-methyl-1H-tetrazol-5-yl]-N-tetrazolyl-2,3,4-triazolyl-1,2,3-trifluoroacetate (salt) (901) (CA INDEX NAME)


13 ANSWER 44 OF 54 CAPLUS COPYRIGHT 2002 APO (continued)

F  
F = 0.02H  
F

PN 156927-00-0 CAPLUS  
CN 3-[[[2-amino-3-methylpentan-3-yl]amino]-4-methyl-1,1,1-trimethyl-5-methyl-1H-tetrazol-5-yl]-N-tetrazolyl-2,3,4-triazolyl-1,2,3-trifluoroacetate (salt) (901) (CA INDEX NAME)

CM 1  
CRN 156926-00-5  
MF 022 H19 N4 O4 2  
CLES \*

Also note stereochemistry.  
Double bond geometry as shown.




CM 2  
CRN 76-05-1  
MF 02 H F3 12

13 ANSWER 44 OF 54 CAPLUS COPYRIGHT 2002 APO (continued)

3-[[[2-amino-3-methylpentan-3-yl]amino]-4-methyl-1,1,1-trimethyl-5-methyl-1H-tetrazol-5-yl]-N-tetrazolyl-2,3,4-triazolyl-1,2,3-trifluoroacetate (salt) (901) (CA INDEX NAME)

CM 1  
CRN 156926-00-4  
MF 023 H19 N4 O3 3  
CLES \*

Also note stereochemistry.  
Double bond geometry as shown.



CM 2  
CRN 76-05-1  
MF 02 H F3 12


F  
F = 0.02H  
F

PN 156928-02-8 CAPLUS  
CN 3-[[[2-amino-3-methylpentan-3-yl]amino]-4-methyl-1,1,1-trimethyl-5-methyl-1H-tetrazol-5-yl]-N-tetrazolyl-2,3,4-triazolyl-1,2,3-trifluoroacetate (salt) (901) (CA INDEX NAME)

CM 1  
CRN 156926-00-4  
MF 024 H19 N4 O3 3  
CLES \*

Also note stereochemistry.  
Double bond geometry as shown.

10. ANSWER 44 OF 56. CALLING SILVERBIRD 200. ALL INFORMATION IS CONFIDENTIAL.



22

CON 75 65 1  
LME 02 H 83



```

FN 156928 06 2  CARBUS
FN Benzenepropionamide, 1, alpha, -{3-[12 amino-3 mercapto propyl]amino}-4
methylhexyl)-N-(tetrahydro-2 H-pyridin-5-yl)-.
[75-{7R-[S*][3R*][S*][4R*]]]-
trifluoroacetate (salt) (1:1) A/A INDEX NAME

```

34 1

SKN 146876-42-4  
 MF 724 H37 N3 C2 3  
 GPC

Arginine stereochemistry.


10 ANSWER 44 OF 59 CALLUS COPYRIGHT 2001 APT (C) 01/04/02

ANSWER:  
M 2

JRN 76-05-1  
MF 42 H P3-32



ANSWER 44 OF 48 APR 13 DREYHOUT 2012 AM 10:05:03



42

JEN 78-06-1  
 MF 78 11 F2 2




24 157-906-62-7 281115

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.25 (d, 2H, ArH), 6.85 (d, 2H, ArH), 6.75 (s, 1H, ArH), 6.65 (s, 1H, ArH), 6.55 (s, 1H, ArH), 6.45 (s, 1H, ArH), 6.35 (s, 1H, ArH), 6.25 (s, 1H, ArH), 6.15 (s, 1H, ArH), 6.05 (s, 1H, ArH), 5.95 (s, 1H, ArH), 5.85 (s, 1H, ArH), 5.75 (s, 1H, ArH), 5.65 (s, 1H, ArH), 5.55 (s, 1H, ArH), 5.45 (s, 1H, ArH), 5.35 (s, 1H, ArH), 5.25 (s, 1H, ArH), 5.15 (s, 1H, ArH), 5.05 (s, 1H, ArH), 4.95 (s, 1H, ArH), 4.85 (s, 1H, ArH), 4.75 (s, 1H, ArH), 4.65 (s, 1H, ArH), 4.55 (s, 1H, ArH), 4.45 (s, 1H, ArH), 4.35 (s, 1H, ArH), 4.25 (s, 1H, ArH), 4.15 (s, 1H, ArH), 4.05 (s, 1H, ArH), 3.95 (s, 1H, ArH), 3.85 (s, 1H, ArH), 3.75 (s, 1H, ArH), 3.65 (s, 1H, ArH), 3.55 (s, 1H, ArH), 3.45 (s, 1H, ArH), 3.35 (s, 1H, ArH), 3.25 (s, 1H, ArH), 3.15 (s, 1H, ArH), 3.05 (s, 1H, ArH), 2.95 (s, 1H, ArH), 2.85 (s, 1H, ArH), 2.75 (s, 1H, ArH), 2.65 (s, 1H, ArH), 2.55 (s, 1H, ArH), 2.45 (s, 1H, ArH), 2.35 (s, 1H, ArH), 2.25 (s, 1H, ArH), 2.15 (s, 1H, ArH), 2.05 (s, 1H, ArH), 1.95 (s, 1H, ArH), 1.85 (s, 1H, ArH), 1.75 (s, 1H, ArH), 1.65 (s, 1H, ArH), 1.55 (s, 1H, ArH), 1.45 (s, 1H, ArH), 1.35 (s, 1H, ArH), 1.25 (s, 1H, ArH), 1.15 (s, 1H, ArH), 1.05 (s, 1H, ArH), 1.95 (s, 1H, ArH), 1.85 (s, 1H, ArH), 1.75 (s, 1H, ArH), 1.65 (s, 1H, ArH), 1.55 (s, 1H, ArH), 1.45 (s, 1H, ArH), 1.35 (s, 1H, ArH), 1.25 (s, 1H, ArH), 1.15 (s, 1H, ArH), 1.05 (s, 1H, ArH), 0.95 (s, 1H, ArH), 0.85 (s, 1H, ArH), 0.75 (s, 1H, ArH), 0.65 (s, 1H, ArH), 0.55 (s, 1H, ArH), 0.45 (s, 1H, ArH), 0.35 (s, 1H, ArH), 0.25 (s, 1H, ArH), 0.15 (s, 1H, ArH), 0.05 (s, 1H, ArH).

1

CEN 16706-61-6  
QMS 120 H31 M3 10 5

Absolute stereochemistry.  
Double bond geometry as in 30. W.



19 ANSWER 45 OF 56 CARLI'S COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1994:551857 CASLUS  
 DOCUMENT NUMBER: 119:155447  
 TITLE: Bi-synthesis and stereo chemistry of the  
 autotransporter

AUTHOR(S):                    Centre for Luminescence in Virology  
                              Lab. de Gènes Moléculaires, Edward A.  
CORRELATE SOURCE:           Dep. Biochem., McGill Univ., Montreal, PQ, H3A  
                              2B6

SOURCE: J. Rastrelli, 110240, 175(12), 3856-w  
 COUNTRY: ITALY; ISSN: 0021-9193

DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB Knowledge of the pathway for synthesis of the auto inducer  
N-(beta, hydroxybutyryl)-L-homoserine lactone (HHL), auto inducing  
substance in *V. fischeri* can provide insight of regulation

the relation between the nutrition and physiol. of the bacteria and the phenomenon of light emission. In this study, the D- and L-iso were of

but induced in it, the stereoisomers of 2-hydroxybutyric acid were synthesized and characterized by proton NMR in the presence of a

shift reagent, 4-mercaptobenzyl deriv. : [115]-(4-mercaptobenzyl)pyr-  
rolic symmetrical (1) sample (at 1). By using a slowly is later  
out (at 1) as

It is shown that autolinker activity was assayed with 1 HMM and not L-HMNL.  
Blockage of fatty acid synthesis by the action of fatty acids

antibiotic treatment the cells prevented synthesis of the autophagosome. If autophagy is induced by the loss of autophagy-inducing activity and a decrease in the concentration of labeled acetate into the partially purified

These results indicate that fatty acid biosynthesis is necessary for light emission in luminous bacteria, because inhibition of synthesis of the

ant. inducer.  
17 **126049-72-7P**  
Eti. CFN (Synthetic preparation); EPER (Preparation)



```

      (approx. and there them. 1. f. Vikari Harvey)
FN 126449 20-2 2A1612
N Botanical, ie. 3-hydroxy N-(4,4'-tetrahydro-2,8-difuranyl)-2,2'-biphenyl-1,1'-dicarboxylic acid
INDEC NAME:


```

Are into space chemistry.  
Currently available space sh. wa.

19 ANSWER 45 OF 56 TAILING OFF/FAINT 20% AND 1% MISSING

[illegible][illegible]

19 ANSWER 46 OF 56 CAPLUS COPYRIGHT 2002 ACS (continued)




```

EN 148433 23-2 7AP10S
TN Hexanamide, 3-hydroxy-N-(tetrahydro-2H-pyran-2-yl)-, [(2S,3R)-]
(19C1)
("A INDEX NAME")
Absolute stereochemistry:

```

Absolute stereochemistry.




```

EN 149413 24 3 "ASLTC"
N Pentanamide, 3-hydroxy-N-(tetrahyr-2H-2-yl-2-ethyl)-13.I 17A
INDEX
NAME)

```

NAME:



```


FN 148472-25-4 "AFL"
FN Hexamethyl-3-lydr 87-N-(1-ethyl-2-oxo-3-ethyl-4-oxo-1,2,3,4-tetrahy-
(201)
(1A INDEX NAME.

```

17A INDEX NAME.

Ats site space chemistry.

L4 ANSWER 45 OF 58 CAPT'S COPYRIGHT 2002 A3 10/1/2002













09587116


15 ANSWER 51 OF 55 CASUS COPYRIGHT 2002 ACS (structural)  
(tetrahydropyran-2-ylidene-1-ylidene-1,3-dioxane)

See literature chemistry.

PAGE 1-A




PAGE 1-B



15 ANSWER 52 OF 55 CASUS COPYRIGHT 2002 ACS (structural)

PAGE 1-C



PAGE 1-D



15 ANSWER 53 OF 55 CASUS COPYRIGHT 2002 ACS

ADDRESS NUMBER: 1985:19417 CASUS

DOCUMENT NUMBER: 10111917

TITLE: General method for the separation of trypan blue

Leu-1

AUTHOR(S):

THIRIATE SOURCE:

207.

SOURCE:

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.

207.


207.

207.


207.

15 ANSWER 54 OF 55 CASUS COPYRIGHT 2002 ACS (structural)


PAGE 1-A



PAGE 1-B





[illegible]

PAGE 1-A

1.9 ANSWER 54 OF 58 CAPLUS COPYRIGHT 2002 AOL All rights reserved





TABLE 2-6




10. 地 址



LAFR 46

2. ANWERFUNG DER VERFAHRENTYPEN UND DER VERFAHRENSSTADIEN

TABLE 2. F



LS - ANSWER 53 00-08 CAPIDS TELEPHONE 2002 ACS  
ACCESSION NUMBER: 1984-073008 CAPIDS  
DOCUMENT NUMBER: 101-732005  
TITLE:  
Immune Modulator sept-168  
INVENTOR(S):  
William, William; Oliver, M; Chan, Edward; Levy  
FACILITY(IES):  
Ehrlich, Albert and Research Foundation, USA  
APPROX: 44 ft.  
CODEN: ETRXW  
DOCUMENT TYPE:  
Patent  
LANGUAGE:  
English  
FAMILY ACQ. NUM. COUNT: 1  
PATENT INFORMATION:

[illegible]

H-Tar-Ile-Ser-Lys-Ala-Lys-Gly-Glu

$$1.61 \times 10^{-3} \text{ g} \cdot \text{cm}^{-3} \cdot \text{s}^{-1} \cdot \text{K}^{-1} \quad 3.16 \times 10^{-3} \text{ g} \cdot \text{cm}^{-3} \cdot \text{s}^{-1} \cdot \text{K}^{-1}$$

1.  $\alpha = 0.05$ ,  $\beta = 0.80$ ,  $\gamma = 0.90$ ,  $\delta = 0.95$ ,  $\epsilon = 0.99$

[illegible]










09587116


12 ANSWER 57 OF 58 CAPLUS COPYRIGHT 2002 ACS (continued)

PAGE 1 A



13 ANSWER 57 OF 58 CAPLUS COPYRIGHT 2002 ACS (continued)

PAGE 1 A



17 71524-85-7W 71524-86-0P 71524-87-9P

71557-81-8P 71663-92-0P  
R10 R11 (Reaction) 22M (Synthetic preparation) 11E1 (Preparation)

(fragm. and peptide coupling reaction) 11


R10 71524-85-7 CAPLUS

R11 N-1-(alpha-Azaphenyl), N2-[N-(1,1,1-trimethyl-4-oxo-2-phenyl-1,2,3,4-tetrahydro-1H-pyridin-2-yl)-L-leucyl]-L-leucyl-L-lysine (14)


methoxycarbonylmethyl-L-lysine (methyl)-L-leucyl-L-N-(tetrahydro-2H-pyran-2-yl-furanyl)-phenylmethyl ester, (S)- (S)- (CA INDEX NAME)

14 ANSWER 57 OF 58 CAPLUS COPYRIGHT 2002 ACS (continued)

PAGE 1-A




PAGE 2-A



R10 71524-85-7 CAPLUS  
R11 N-1-(alpha-Azaphenyl), N2-[N-(1,1,1-trimethyl-4-oxo-2-phenyl-1,2,3,4-tetrahydro-1H-pyridin-2-yl)-L-leucyl]-L-leucyl-L-lysine (14)  
methoxycarbonylmethyl-L-lysine (methyl)-L-leucyl-L-N-(tetrahydro-2H-pyran-2-yl-furanyl)-phenylmethyl ester, (S)- (S)- (CA INDEX NAME)

15 ANSWER 57 OF 58 CAPLUS COPYRIGHT 2002 ACS (continued)

PAGE 1-A



PAGE 2 A



R10 71524-85-7 CAPLUS  
R11 N-1-(alpha-Azaphenyl), N2-[N-(1,1,1-trimethyl-4-oxo-2-phenyl-1,2,3,4-tetrahydro-1H-pyridin-2-yl)-L-leucyl]-L-leucyl-L-lysine (14)  
methoxycarbonylmethyl-L-lysine (methyl)-L-leucyl-L-N-(tetrahydro-2H-pyran-2-yl-furanyl)-phenylmethyl ester, (S)- (S)- (CA INDEX NAME)

As a late stage chemist.







09587116

13 ANSWER SHEET FOR TABLETS OF ERYTHROMETHYLATE

PAGE 1 A



PAGE 1 B



14 ANSWER SHEET FOR TABLETS OF ERYTHROMETHYLATE

PAGE 1 B



09587116

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	259.27	548.50

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-35.93	-35.93

FILE 'STNGUIDE' ENTERED AT 16:32:32 ON 18 JAN 2002  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Jan 11, 2002 (20020111/UF).

=> d his

(FILE 'HOME' ENTERED AT 16:21:30 ON 18 JAN 2002)

FILE 'REGISTRY' ENTERED AT 16:21:41 ON 18 JAN 2002

L1	STRUCTURE UPLOADED
L2	249 S L1 FUL
L3	240 S L2 AND CAPLUS/LC
L4	9 S L2 NOT L3
L5	STRUCTURE UPLOADED
L6	232 S L5 FUL
L7	223 S L6 AND CAPLUS/LC
L8	9 S L6 NOT L7

FILE 'CAPLUS' ENTERED AT 16:23:51 ON 18 JAN 2002

L9	58 S L7
----	---------

FILE 'STNGUIDE' ENTERED AT 16:32:32 ON 18 JAN 2002

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.00	548.50

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-35.93

FILE 'REGISTRY' ENTERED AT 16:33:05 ON 18 JAN 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 16 JAN 2002 HIGHEST RN 383858-27-3  
DICTIONARY FILE UPDATES: 16 JAN 2002 HIGHEST RN 383858-27-3

09587116

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES  
for more information. See STNote 27, Searching Properties in the CAS  
Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d his

(FILE 'HOME' ENTERED AT 16:21:30 ON 18 JAN 2002)

FILE 'REGISTRY' ENTERED AT 16:21:41 ON 18 JAN 2002

L1           STRUCTURE UPLOADED  
L2           249 S L1 FUL  
L3           240 S L2 AND CAPLUS/LC  
L4           9 S L2 NOT L3  
L5           STRUCTURE UPLOADED  
L6           232 S L5 FUL  
L7           223 S L6 AND CAPLUS/LC  
L8           9 S L6 NOT L7

FILE 'CAPLUS' ENTERED AT 16:23:51 ON 18 JAN 2002

L9           58 S L7

FILE 'STNGUIDE' ENTERED AT 16:32:32 ON 18 JAN 2002

FILE 'REGISTRY' ENTERED AT 16:33:05 ON 18 JAN 2002

=> s l2 not l6

L10          17 L2 NOT L6

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.32	548.82
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-35.93

FILE 'CAPLUS' ENTERED AT 16:33:29 ON 18 JAN 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

09587116

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1907 - 18 Jan 2002 VOL 136 ISS 3  
FILE LAST UPDATED: 16 Jan 2002 (20020116/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAPLUS now provides online access to patents and literature covered in CA from 1907 to the present. Bibliographic information and abstracts were added in 2001 for over 3.8 million records from 1907-1966.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

Attention, the CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


=> s l10  
l11 9 l10

=> d 1-9 ibib abs hitstr




[illegible][illegible]

211 ANSWER 1 OF 9 TAIUNG COPYRIGHT 2002 ACS 17 61166-1  
Absolute stereochemistry.




IT 345234-98-2P  
 PL: NOT Intermediate: DIN (Synthetic) preparata nlr IREI (Preparata nlr  
 Intermediate) synthetice and use: f. hystericum: and lerpum, as  
 inhibitor of human TGF $\alpha$ , TNF,  $\alpha$ lpha, release and  $\beta$ -lactamase.  
 CN 345234-98-2 CAPLUS  
 GN 2-Naphthalenolmethanone acid,  
 $\alpha$ -lipoic, hydroxy, beta, (11105)-tetrahydropyridine, 4,4-  
 dimethyl-, w-2-furanylaminic, 1-yl, w-1,1-dimethylethyl ester,  
 1,1,1,1-tetrahydro-2,2,2,2-tetrazol-4-yl, 1,1,1,1-tetrahydro-2,2,2,2-  
 tetrazol-4-yl, (271) CA, INDEX, NAME

As in its store chemistry.

[illegible]


As a consequence, the following

111 ANSWER: 1 OF 2 "AFLUO" "FYEHT" "LOL" ARE "O" "AFLUO" "FYEHT" "LOL" ARE "O" "AFLUO" "FYEHT" "LOL" ARE "O"



A: 1 mg/kg, i.p. formula is claimed [wherein R<sub>1</sub> is methyl, R<sub>2</sub> is triethylammonium, the substituents chosen from alkyl, allyl, aryl, aralkyl, heteroalkyl, cycloalkyl, R<sub>3</sub>, R<sub>4</sub> = alkyl, the example is provided (1). The process claimed involves step (a) to (c) as follows: (a) a mixture of 1-methyl-2-allyl-3-allyl-4-allyl-5-allyl-6-allyl-7-allyl-8-allyl-9-allyl-10-allyl-11-allyl-12-allyl-13-allyl-14-allyl-15-allyl-16-allyl-17-allyl-18-allyl-19-allyl-20-allyl-21-allyl-22-allyl-23-allyl-24-allyl-25-allyl-26-allyl-27-allyl-28-allyl-29-allyl-30-allyl-31-allyl-32-allyl-33-allyl-34-allyl-35-allyl-36-allyl-37-allyl-38-allyl-39-allyl-40-allyl-41-allyl-42-allyl-43-allyl-44-allyl-45-allyl-46-allyl-47-allyl-48-allyl-49-allyl-50-allyl-51-allyl-52-allyl-53-allyl-54-allyl-55-allyl-56-allyl-57-allyl-58-allyl-59-allyl-60-allyl-61-allyl-62-allyl-63-allyl-64-allyl-65-allyl-66-allyl-67-allyl-68-allyl-69-allyl-70-allyl-71-allyl-72-allyl-73-allyl-74-allyl-75-allyl-76-allyl-77-allyl-78-allyl-79-allyl-80-allyl-81-allyl-82-allyl-83-allyl-84-allyl-85-allyl-86-allyl-87-allyl-88-allyl-89-allyl-90-allyl-91-allyl-92-allyl-93-allyl-94-allyl-95-allyl-96-allyl-97-allyl-98-allyl-99-allyl-100-allyl-101-allyl-102-allyl-103-allyl-104-allyl-105-allyl-106-allyl-107-allyl-108-allyl-109-allyl-110-allyl-111-allyl-112-allyl-113-allyl-114-allyl-115-allyl-116-allyl-117-allyl-118-allyl-119-allyl-120-allyl-121-allyl-122-allyl-123-allyl-124-allyl-125-allyl-126-allyl-127-allyl-128-allyl-129-allyl-130-allyl-131-allyl-132-allyl-133-allyl-134-allyl-135-allyl-136-allyl-137-allyl-138-allyl-139-allyl-140-allyl-141-allyl-142-allyl-143-allyl-144-allyl-145-allyl-146-allyl-147-allyl-148-allyl-149-allyl-150-allyl-151-allyl-152-allyl-153-allyl-154-allyl-155-allyl-156-allyl-157-allyl-158-allyl-159-allyl-160-allyl-161-allyl-162-allyl-163-allyl-164-allyl-165-allyl-166-allyl-167-allyl-168-allyl-169-allyl-170-allyl-171-allyl-172-allyl-173-allyl-174-allyl-175-allyl-176-allyl-177-allyl-178-allyl-179-allyl-180-allyl-181-allyl-182-allyl-183-allyl-184-allyl-185-allyl-186-allyl-187-allyl-188-allyl-189-allyl-190-allyl-191-allyl-192-allyl-193-allyl-194-allyl-195-allyl-196-allyl-197-allyl-198-allyl-199-allyl-200-allyl-201-allyl-202-allyl-203-allyl-204-allyl-205-allyl-206-allyl-207-allyl-208-allyl-209-allyl-210-allyl-211-allyl-212-allyl-213-allyl-214-allyl-215-allyl-216-allyl-217-allyl-218-allyl-219-allyl-220-allyl-221-allyl-222-allyl-223-allyl-224-allyl-225-allyl-226-allyl-227-allyl-228-allyl-229-allyl-230-allyl-231-allyl-232-allyl-233-allyl-234-allyl-235-allyl-236-allyl-237-allyl-238-allyl-239-allyl-240-allyl-241-allyl-242-allyl-243-allyl-244-allyl-245-allyl-246-allyl-247-allyl-248-allyl-249-allyl-250-allyl-251-allyl-252-allyl-253-allyl-254-allyl-255-allyl-256-allyl-257-allyl-258-allyl-259-allyl-260-allyl-261-allyl-262-allyl-263-allyl-264-allyl-265-allyl-266-allyl-267-allyl-268-allyl-269-allyl-270-allyl-271-allyl-272-allyl-273-allyl-274-allyl-275-allyl-276-allyl-277-allyl-278-allyl-279-allyl-280-allyl-281-allyl-282-allyl-283-allyl-284-allyl-285-allyl-286-allyl-287-allyl-288-allyl-289-allyl-290-allyl-291-allyl-292-allyl-293-allyl-294-allyl-295-allyl-296-allyl-297-allyl-298-allyl-299-allyl-300-allyl-301-allyl-302-allyl-303-allyl-304-allyl-305-allyl-306-allyl-307-allyl-308-allyl-309-allyl-310-allyl-311-allyl-312-allyl-313-allyl-314-allyl-315-allyl-316-allyl-317-allyl-318-allyl-319-allyl-320-allyl-321-allyl-322-allyl-323-allyl-324-allyl-325-allyl-326-allyl-327-allyl-328-allyl-329-allyl-330-allyl-331-allyl-332-allyl-333-allyl-334-allyl-335-allyl-336-allyl-337-allyl-338-allyl-339-allyl-340-allyl-341-allyl-342-allyl-343-allyl-344-allyl-345-allyl-346-allyl-347-allyl-348-allyl-349-allyl-350-allyl-351-allyl-352-allyl-353-allyl-354-allyl-355-allyl-356-allyl-357-allyl-358-allyl-359-allyl-360-allyl-361-allyl-362-allyl-363-allyl-364-allyl-365-allyl-366-allyl-367-allyl-368-allyl-369-allyl-370-allyl-371-allyl-372-allyl-373-allyl-374-allyl-375-allyl-376-allyl-377-allyl-378-allyl-379-allyl-380-allyl-381-allyl-382-allyl-383-allyl-384-allyl-385-allyl-386-allyl-387-allyl-388-allyl-389-allyl-390-allyl-391-allyl-392-allyl-393-allyl-394-allyl-395-allyl-396-allyl-397-allyl-398-allyl-399-allyl-400-allyl-401-allyl-402-allyl-403-allyl-404-allyl-405-allyl-406-allyl-407-allyl-408-allyl-409-allyl-410-allyl-411-allyl-412-allyl-413-allyl-414-allyl-415-allyl-416-allyl-417-allyl-418-allyl-419-allyl-420-allyl-421-allyl-422-allyl-423-allyl-424-allyl-425-allyl-426-allyl-427-allyl-428-allyl-429-allyl-430-allyl-431-allyl-432-allyl-433-allyl-434-allyl-435-allyl-436-allyl-437-allyl-438-allyl-439-allyl-440-allyl-441-allyl-442-allyl-443-allyl-444-allyl-445-allyl-446-allyl-447-allyl-448-allyl-449-allyl-450-allyl-451-allyl-452-allyl-453-allyl-454-allyl-455-allyl-456-allyl-457-allyl-458-allyl-459-allyl-460-allyl-461-allyl-462-allyl-463-allyl-464-allyl-465-allyl-466-allyl-467-allyl-468-allyl-469-allyl-470-allyl-471-allyl-472-allyl-473-allyl-474-allyl-475-allyl-476-allyl-477-allyl-478-allyl-479-allyl-480-allyl-481-allyl-482-allyl-483-allyl-484-allyl-485-allyl-486-allyl-487-allyl-488-allyl-489-allyl-490-allyl-491-allyl-492-allyl-493-allyl-494-allyl-495-allyl-496-allyl-497-allyl-498-allyl-499-allyl-500-allyl-501-allyl-502-allyl-503-allyl-504-allyl-505-allyl-506-allyl-507-allyl-508-allyl-509-allyl-510-allyl-511-allyl-512-allyl-513-allyl-514-allyl-515-allyl-516-allyl-517-allyl-518-allyl-519-allyl-520-allyl-521-allyl-522-allyl-523-allyl-524-allyl-525-allyl-526-allyl-527-allyl-528-allyl-529-allyl-530-allyl-531-allyl-532-allyl-533-allyl-534-allyl-535-allyl-536-allyl-537-allyl-538-allyl-539-allyl-540-allyl-541-allyl-542-allyl-543-allyl-544-allyl-545-allyl-546-allyl-547-allyl-548-allyl-549-allyl-550-allyl-551-allyl-552-allyl-553-allyl-554-allyl-555-allyl-556-allyl-557-allyl-558-allyl-559-allyl-560-allyl-561-allyl-562-allyl-563-allyl-564-allyl-565-allyl-566-allyl-567-allyl-568-allyl-569-allyl-570-allyl-571-allyl-572-allyl-573-allyl-574-allyl-575-allyl-576-allyl-577-allyl-578-allyl-579-allyl-580-allyl-581-allyl-582-allyl-583-allyl-5

LL: ANSWER 1 OF 9 FILES COPYRIGHT 2004 ACS ID: 51104-9




```

EN 345235-61-0 "AFLUB"
IN 2 Naphthalenehexanone and,
alpha prop xylyl ketone, [111] 4,4-tetrahyd-4,4
dimethyl 2 x-3 furanylamine [ark nyl-, 1,1-dimethylethyl ester,
dimethyl 2,2,2,4,4,4-hexafluoro-1,3-bis(4-oxo-1,2,3,4-tetrahydropyridin-2-yl)] (CA INDEX NAME)

```

Absolute stereochemistry.



```

IN  4414 02 1  'ALPHO
IN  2-Naphtol:ekutan 10 word.
.alpha.p.p.xv.beta.[[(10) tetrahydr 4,4-
dimethyl 2-xo-6-formyl]amin'ter'nyl], .alpha.2.beta.0 10
IA
'KEY: NAME

```


Are there other elements...





$$\begin{array}{c} \text{NH} \\ | \\ \text{H} - \text{C} - \text{H} \\ | \\ \text{H} \end{array} \quad \begin{array}{c} \text{NH} \\ | \\ \text{H} - \text{C} - \text{H} \\ | \\ \text{H} \end{array} \quad \begin{array}{c} \text{NH} \\ | \\ \text{H} - \text{C} - \text{H} \\ | \\ \text{H} \end{array} \quad \begin{array}{c} \text{NH} \\ | \\ \text{H} - \text{C} - \text{H} \\ | \\ \text{H} \end{array}$$



[illegible]

09587116

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

39.84

588.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-5.58

-41.51

FILE 'REGISTRY' ENTERED AT 16:34:10 ON 18 JAN 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 16 JAN 2002 HIGHEST RN 383858-27-3

DICTIONARY FILE UPDATES: 16 JAN 2002 HIGHEST RN 383858-27-3

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES  
for more information. See STNote 27, Searching Properties in the CAS  
Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d his

(FILE 'HOME' ENTERED AT 16:21:30 ON 18 JAN 2002)

FILE 'REGISTRY' ENTERED AT 16:21:41 ON 18 JAN 2002

L1 STRUCTURE UPLOADED  
L2 249 S L1 FUL  
L3 240 S L2 AND CAPLUS/LC  
L4 9 S L2 NOT L3  
L5 STRUCTURE UPLOADED  
L6 232 S L5 FUL  
L7 223 S L6 AND CAPLUS/LC  
L8 9 S L6 NOT L7

FILE 'CAPLUS' ENTERED AT 16:23:51 ON 18 JAN 2002

L9 58 S L7

FILE 'STNGUIDE' ENTERED AT 16:32:32 ON 18 JAN 2002

FILE 'REGISTRY' ENTERED AT 16:33:05 ON 18 JAN 2002

L10 17 S L2 NOT L6

FILE 'CAPLUS' ENTERED AT 16:33:29 ON 18 JAN 2002

09587116

L11

9 S L10

FILE 'REGISTRY' ENTERED AT 16:34:10 ON 18 JAN 2002

=> d 14 1-9




09587116

```

14 ANSWER 1 IF - REACTIVITY - HYPERMETROIC ACT
EN TITRATION 4 REACTIVITY
FN TitrationName: -hydroxy N tetraamino-2-methyl-6-amino-7-oxo-8-phenyl-9H-pyrazolo[4,5-d]pyrimidin-9-one
FD INDEX NAME:
MF 3L TITRATN
MR 05 HXK 04
MI DM
ME PA

```



\*\*\*PROPERTY DATA AVAILABLE IN THE 'PEEF' FORMAT\*\*\*

[illegible]

At the same time, chemistry,  
biology and geology are also well-




\*\*\* FIFTY DATA AVAILABLE IN THE "SECS" FORMAT \*\*\*

```

LN ANSWER 3 OF REGISTRY COPYRIGHT 2002 AJS
M 16627-91-2 REGISTRY
CN 3-oxetanamide, 5-[(2-amino-4-methyl-5-pyrimidin-6-yl)methyl]-2-[1-
methylpropyl]-N-(2-ethyl-2-methylfuran-2-yl)-
[3R,4Z][2S,3R,4E,5R,6S,6R]] (SICI) (CA INDEX NAME)
F3 STEREOBOND
MF C22 H37 N3 O3
C1 COM
PB Cyl

```

And late stereo chemistry.  
Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'E' FORMAT\*\*

```

L4 ANSWER 4 OF 2:  REGISTRY COPYRIGHT 2002 AT&T
IN 109721-84-8 REGISTRY
FN Butyric acid, 2-(4-oxo-4-oxaminohexanamido)-, 4-hydroxy-,
gamma-lactone,
benzyl ester (601) (CA INDEX NAME)
FS NO CONCORD
MF 016 H24 N2 05

```

STN Files: REILSTEIN\*, \*OLD  
\*File : nta;no numerically searchable property data:



\*\*\*PROPERTY DATA AVAILABLE IN THE "PROP" FORMAT\*\*\*

1. REFERENCES IN FILE "A LE 1961: B TO 1969"



09587116

[illegible]

09587116

=> d his

(FILE 'HOME' ENTERED AT 16:21:30 ON 18 JAN 2002)

FILE 'REGISTRY' ENTERED AT 16:21:41 ON 18 JAN 2002

L1           STRUCTURE UPLOADED  
L2           249 S L1 FUL  
L3           240 S L2 AND CAPLUS/LC  
L4           9 S L2 NOT L3  
L5           STRUCTURE UPLOADED  
L6           232 S L5 FUL  
L7           223 S L6 AND CAPLUS/LC  
L8           9 S L6 NOT L7

FILE 'CAPLUS' ENTERED AT 16:23:51 ON 18 JAN 2002

L9           58 S L7

FILE 'STNGUIDE' ENTERED AT 16:32:32 ON 18 JAN 2002

FILE 'REGISTRY' ENTERED AT 16:33:05 ON 18 JAN 2002

L10          17 S L2 NOT L6

FILE 'CAPLUS' ENTERED AT 16:33:29 ON 18 JAN 2002


L11          9 S L10

FILE 'REGISTRY' ENTERED AT 16:34:10 ON 18 JAN 2002

=> d 18 1-9

09587116


LE ANSWER 1 OF 9 REGISTRY COPYRIGHT 2002 ACS  
 RN 159979-55-4 REGISTRY  
 IN Tetrahydro-2H-pyran-2-ylidene-1,4-dioxane-5-carboxylic acid  
 PS 15 159979  
 MF C12H16O4  
 CI 1M  
 SP 1A



\*\*\*PROPERTY DATA AVAILABLE IN THE 'PUB' FORMAT\*\*\*

LE ANSWER 2 OF 9 REGISTRY COPYRIGHT 2002 ACS  
 RN 159979-55-4 REGISTRY  
 IN Tetrahydro-2H-pyran-2-ylidene-1,4-dioxane-5-carboxylic acid  
 PS 15 159979  
 MF C12H16O4  
 CI 1M  
 SP 1A


APR 1998 stereochemistry  
 Double bond geometry as shown.



\*\*\*PROPERTY DATA AVAILABLE IN THE 'PUB' FORMAT\*\*\*

LE ANSWER 3 OF 9 REGISTRY COPYRIGHT 2002 ACS  
 RN 159979-55-4 REGISTRY  
 IN Tetrahydro-2H-pyran-2-ylidene-1,4-dioxane-5-carboxylic acid  
 PS 15 159979  
 MF C12H16O4  
 CI 1M  
 SP 1A

APR 1998 stereochemistry  
 Double bond geometry as shown.



\*\*\*PROPERTY DATA AVAILABLE IN THE 'PUB' FORMAT\*\*\*

LE ANSWER 4 OF 9 REGISTRY COPYRIGHT 2002 ACS  
 RN 159979-55-4 REGISTRY  
 IN Tetrahydro-2H-pyran-2-ylidene-1,4-dioxane-5-carboxylic acid  
 PS 15 159979  
 MF C12H16O4  
 CI 1M  
 SP 1A

APR 1998 stereochemistry  
 Double bond geometry as shown.




\*\*\*PROPERTY DATA AVAILABLE IN THE 'PUB' FORMAT\*\*\*

1 REFERRED IN FILE 'ACID' FROM 15 159979

09587116

LA ANSWER 4 OF 5 REGISTRY COPYRIGHT 1990 ACS  
 RN 108237-44-0 REGISTRY  
 CN Butyric acid, 2-(4-hydroxyphenyl) propionyl 4-hydroxy-  
 phenyl ester (1:1) (CA INDEX NAME)  
 ES AD CONCORD  
 MF C14 H14 NO 5  
 OS CACD  
 LT STN File(s): PEILSTEIN\*, CACD  
 \*File contains numerically searchable property data




\*\*\*PROPERTY DATA AVAILABLE IN THE "PEIL" FORMAT\*\*\*  
 1 REFERENCED IN FILE CACD (1984 TO 1987)

LA ANSWER 4 OF 5 REGISTRY COPYRIGHT 1990 ACS  
 RN 108237-44-0 REGISTRY  
 CN Butyric acid, 2-(4-hydroxyphenyl) propionyl 4-hydroxy-  
 phenyl ester (1:1) (CA INDEX NAME)  
 ES AD CONCORD  
 MF C14 H14 NO 5  
 OS CACD  
 LT STN File(s): PEILSTEIN\*, CACD  
 \*File contains numerically searchable property data




\*\*\*PROPERTY DATA AVAILABLE IN THE "PEIL" FORMAT\*\*\*  
 1 REFERENCED IN FILE CACD (1984 TO 1987)

LA ANSWER 7 OF 9 REGISTRY COPYRIGHT 1990 ACS  
 RN 101873-16-9 REGISTRY  
 CN Deoxydianide, N,N'-bis(2-ethyl-2-oxo-1,3-dioxol-5-yl) (1:1) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Butyric acid, 2,2'-(2-oxo-1,3-dioxol-5-ylidene) bis[4-hydroxy-3-oxo-1,4-dihydro-2H-pyran-1-ylidene] (1:1)  
 ES AD CONCORD  
 MF C18 H24 NO 8  
 OS CACD  
 LT STN File(s): PEILSTEIN\*, CACD  
 \*File contains numerically searchable property data



\*\*\*PROPERTY DATA AVAILABLE IN THE "PEIL" FORMAT\*\*\*  
 1 REFERENCED IN FILE CACD (1984 TO 1987)

LA ANSWER 4 OF 5 REGISTRY COPYRIGHT 1990 ACS  
 RN 100876-51-9 REGISTRY  
 CN Butyric acid, 2,2'-(2-oxo-1,3-dioxol-5-ylidene) bis[4-hydroxy-3-oxo-1,4-dihydro-2H-pyran-1-ylidene] (1:1) (CA INDEX NAME)  
 ES AD CONCORD  
 MF C14 H20 NO 8  
 OS CACD  
 LT STN File(s): PEILSTEIN\*, CACD  
 \*File contains numerically searchable property data



\*\*\*PROPERTY DATA AVAILABLE IN THE "PEIL" FORMAT\*\*\*  
 1 REFERENCED IN FILE CACD (1984 TO 1987)



09587116

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	29.08	617.74
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-41.51

FILE 'REGISTRY' ENTERED AT 16:35:21 ON 18 JAN 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 16 JAN 2002 HIGHEST RN 383858-27-3  
DICTIONARY FILE UPDATES: 16 JAN 2002 HIGHEST RN 383858-27-3

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES  
for more information. See STNote 27, Searching Properties in the CAS  
Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> SET TERMSET E#

SET COMMAND COMPLETED

=> DEL SEL Y

=> SEL L8 9 RN

E1 THROUGH E1 ASSIGNED

=> S E1/RN

L12 1 90607-30-0/RN

=> SET TERMSET LOGIN

SET COMMAND COMPLETED

=> FIL CAOLD

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
----------------------	------------	-------



09587116

FULL ESTIMATED COST	ENTRY 0.40	SESSION 618.14
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-41.51

FILE 'CAOLD' ENTERED AT 16:35:34 ON 18 JAN 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966  
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> S L12

L13            1 L12

=> DIS L13 1 HITSTR



09587116

=> DIS L13 1 ALL



09587116

=> DIS L13 1 IBIB

09587116

UN ANSWER 1 OF 1 PAGE 1 COPYRIGHT 1980 AFS  
ACCESSION NUMBER: 09587116 PAGE 1  
TITLE: KINETICS OF THE POLYMERIZATION OF HYDROLYZABLE  
IN  
AUTHOR NAME: S. Ito  
P. Kuroki, S. Kawai


09587116

=> DIS L13 1 IALL

I6 ANSWER 296 OF 336 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 1986:28848 CAPLUS  
 DOCUMENT NUMBER: 104:28848  
 TITLE: .alpha.-Amino-.gamma.-butyrolactone derivatives and  
 pharmaceutical compositions containing them  
 INVENTOR(S): Tessitore, Pietro Tomaso  
 PATENT ASSIGNEE(S): Laboratorio Farmaceutico CT S.r.l., Italy  
 SOURCE: Eur. Pat. Appl., 21 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 151964	A2	19850821	EP 1985-100564	19850120
EP 151964	A3	19860305		

R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE  
 PRIORITY APPLN. INFO.: IT 1984-19390 19840202  
 GI




AB .alpha.-Amino-.gamma.-butyrolactone derivs. of formula I (where R =  
 linear  
 or branched C4-8 alkyl; or R = OR<sub>1</sub> where R<sub>1</sub> = linear or branched C1-5  
 alkyl; n = 0 when R = alkyl; n = 1-5 when R = OR<sub>1</sub>) are prep'd. and tested  
 for their anticonvulsant, antiepileptic, and sedative actions. Thus,  
 .alpha.-amino-.gamma.-butyrolactone, dissolved in pyridine, reacted with  
 PrCOCl at 0.degree. to form .alpha.-butyrylamino-.gamma.-butyrolactone  
 (II), which had an LD<sub>50</sub> in rats of >2 g/kg. The highest oral dose  
 produced a sedative effect but did not cause loss of the righting reflex;  
 however, the sedative effect was obtained with the lowest i.p. dose and  
 at 1 g/kg the righting reflex was lost. II was effective in protecting mice  
 from death caused by strychnine injection and was as effective as  
 phenobarbital in protecting mice from electroshock.  
 IT **98426-48-3P 99063-14-6P 99740-62-2P**  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as central nervous system depressant and for treatment of  
 alcoholism)  
 RN 98426-48-3 CAPLUS  
 CN Butanamide, N-(tetrahydro-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)






RN 99063-14-6 CAPLUS

CN Pentanamide, N-(tetrahydro-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)



RN 99740-62-2 CAPLUS

CN Propanamide, 2-methyl-N-(tetrahydro-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)




L6 ANSWER 291 OF 336 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 1987:99288 CAPLUS  
 DOCUMENT NUMBER: 106:99288  
 TITLE: Analogs of the autoinducer of bioluminescence in  
 Vibrio fischeri  
 AUTHOR(S): Eberhard, Anatol; Widrig, Cindra A.; McBath, Paula;  
 Schineller, Jeffrey B.  
 CORPORATE SOURCE: Dep. Chem., Ithaca Coll., Ithaca, NY, 14850, USA  
 SOURCE: Arch. Microbiol. (1986), 146(1), 35-40  
 CODEN: AMICCW; ISSN: 0302-8933  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The enzymes for luminescence in *V. fischeri* are induced only when a  
 sufficient concn. of a metabolic product (autoinducer) specifically  
 produced by this species accumulates. It has previously been shown that  
 the autoinducer is 3-oxohexanoyl homoserine lactone and that it enters

the cells by simple diffusion. To further study the mechanism of induction,  
 several analogs of the autoinducer were synthesized and tested with *V.*  
*fischeri* for their inducing activity and for their ability to inhibit the  
 action of the natural autoinducer. The compds. displayed various  
 combinations of inducing and inhibiting abilities. None of the compds.  
 tested appeared to have any effect on cells of *V. harveyi* strain MAV or  
*Photobacterium leiognathi* strain 721, but several of the compds.


decreased  
 light output by *P. phosphoreum* strain 8265. These studies show (1) the  
 site of action of the autoinducer is not highly sterically constrained,  
 (2) the autoinducers of other species of luminous bacteria are likely to  
 be quite different from that of *V. fischeri*, and (3) a simple mode in  
 which one autoinducer mol. binds to a single receptor protein site and  
 thus, initiates luciferase synthesis if inadequate. The analogs should  
 prove useful in the study of the binding site and mode of action of the  
 autoinducer.

IT 76924-95-3  
 RL: BIOL (Biological study)  
 (bioluminescence by *Vibrio fischeri* induction by, analogs effect on)  
 RN 76924-95-3 CAPLUS  
 CN Hexanamide, 3-oxo-N-(tetrahydro-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)




IT 76924-95-3D, derivs. 98318-13-9 98426-48-3  
 99063-14-6 106983-26-0 106983-27-1  
 106983-28-2 106983-29-3 106983-30-6  
 106983-31-7 106983-32-8 106983-33-9  
 106983-34-0 106983-35-1 106983-36-2  
 106999-81-9  
 RL: BAC (Biological activity or effector, except adverse); BIOL  
 (Biological study)  
 (bioluminescence by *Vibrio fischeri* response to)


RN 76924-95-3 CAPLUS  
 CN Hexanamide, 3-oxo-N-(tetrahydro-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)




RN 98318-13-9 CAPLUS  
 CN 4-Hexenamide, 3-oxo-N-(tetrahydro-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)




RN 98426-48-3 CAPLUS  
 CN Butanamide, N-(tetrahydro-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)




RN 99063-14-6 CAPLUS  
 CN Pentanamide, N-(tetrahydro-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)




RN 106983-26-0 CAPLUS  
 CN Heptanamide, N-(tetrahydro-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)







RN 106983-27-1 CAPLUS  
CN Octanamide, 3-oxo-N-(tetrahydro-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)




RN 106983-28-2 CAPLUS  
CN Hexanamide, N-(tetrahydro-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)




RN 106983-29-3 CAPLUS  
CN Butanamide, 3-oxo-N-(tetrahydro-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)



RN 106983-30-6 CAPLUS  
CN Octanamide, N-(tetrahydro-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)




RN 106983-31-7 CAPLUS  
CN Octanamide, 2-oxo-N-(tetrahydro-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)




RN 106983-32-8 CAPLUS

CN Nonanamide, N-(tetrahydro-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)




RN 106983-33-9 CAPLUS

CN Butanamide, 2-oxo-N-(tetrahydro-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)




RN 106983-34-0 CAPLUS

CN Butanoic acid, 4-oxo-4-[(tetrahydro-2-oxo-3-furanyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 106983-35-1 CAPLUS

CN Hexanamide, 2-oxo-N-(tetrahydro-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)



RN 106983-36-2 CAPLUS

CN Decanamide, N-(tetrahydro-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)



RN 106999-81-9 CAPLUS

CN Hexanamide, 5-oxo-N-(tetrahydro-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)

